



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain / Falsini M.; Catarzi D.; Varano F.; Ceni C.; Dal Ben D.; Marucci G.; Buccioni M.; Volpini R.; Di Cesare Mannelli L.; Lucarini E.; Ghelardini C.; Bartolucci G.; Menicatti M.; Colotta V.. - In: JOURNAL OF MEDICINAL CHEMISTRY.

Availability:

The webpage <https://hdl.handle.net/2158/1172829> of the repository was last updated on 2024-04-22T13:24:54Z

Published version:

DOI: 10.1021/acs.jmedchem.9b00778

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain

Matteo Falsini, Daniela Catarzi, Flavia Varano, Costanza Ceni, Diego Dal Ben, Gabriella Marucci, Michela Buccioni, Rosaria Volpini, Lorenzo Di Cesare Mannelli, Elena Lucarini, Carla Ghelardini, Gianluca Bartolucci, Marta Menicatti, and Vittoria Colotta

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.9b00778 • Publication Date (Web): 27 Aug 2019

Downloaded from pubs.acs.org on September 2, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5 **Antioxidant-conjugated 1,2,4-Triazolo[4,3-*a*]pyrazin-3-one**
6
7
8 **Derivatives: Highly Potent and Selective Human A_{2A}**
9
10 **Adenosine Receptor Antagonists Possessing Protective**
11
12 **Efficacy in Neuropathic Pain**
13
14
15
16
17
18

19 Matteo Falsini,^a Daniela Catarzi,^a Flavia Varano,^a Costanza Ceni,^a Diego Dal Ben,^b Gabriella
20 Marucci,^b Michela Buccioni,^b Rosaria Volpini,^b Lorenzo Di Cesare Mannelli,^c Elena Lucarini,^c
21
22
23
24 Carla Ghelardini,^c Gianluca Bartolucci,^a Marta Menicatti,^a Vittoria Colotta^{a*}
25

26 ^a*Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e*
27 *Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, 50019 Sesto Fiorentino, Italy.*

30 ^b*Scuola di Scienze del Farmaco e dei Prodotti della Salute, Università degli Studi di Camerino, via S. Agostino 1,*
31 *62032 Camerino (MC), Italy.*

33 ^c*Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmacologia e*
34 *Tossicologia, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy.*
35
36
37
38
39

40 **Key words:** G protein-coupled receptors, A_{2A} adenosine receptor antagonists, 1,2,4-triazolo[4,3-
41 *a*]pyrazin-3-one, neuropathic pain, ligand-adenosine receptor modeling studies.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

New 8-amino-6-aryl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3-ones were designed to obtain dual antioxidant-human A_{2A} adenosine receptor (hA_{2A} AR) antagonists. Two sets of compounds were synthesized, the first featuring phenol rings at the 6-position, the second bearing the lipoyl and 4-hydroxy-3,5-di-terbut-benzoyl residues appended by different linkers on the 6-phenyl ring. Several new triazolopyrazines (**1-21**) were potent and selective hA_{2A} AR antagonists (K_i= 0.17-54.5 nM). Compounds **11**, **15** and **21**, featuring antioxidant moieties, and compound **12**, lacking the antioxidant functionality, reduced oxaliplatin-induced toxicity in microglia cells, the most active being the lipoyl-derivative **15** and the (4-hydroxy-3,5-di-tert-butyl)phenyl- analogue **21** which were effective in reducing the oxygen free radical level. The lipoyl-derivative **15** was also able to revert oxaliplatin-induced neuropathy in mouse. In vivo efficacy of **15** makes it a promising neuroprotective agent in oxidative stress-related diseases.

INTRODUCTION

The endogenous nucleoside adenosine affects many pathophysiological conditions through activation of G protein-coupled receptors classified as A₁, A_{2A}, A_{2B} and A₃ receptors. A_{2A} AR stimulation increases adenylate cyclase activity and cAMP production, thus activating protein kinase A and the mitogen-activated protein kinases p38, ERK1/2 and JNK1/2.^{1,2}


The A_{2A} AR subtype is expressed in the central nervous system (CNS) showing the greatest density in the striatum, olfactory tubercle and nucleus accumbens while lower levels are present in the cortex and hippocampus. In periphery, the A_{2A} AR is abundant in heart, lung, blood vessels and in the immune system.

The A_{2A} AR plays a key role in the regulation of inflammatory processes both in the CNS and in periphery.¹⁻⁴ At peripheral level, it activates an anti-inflammatory cascade through a reduced functionality of the immune system cells and inflammatory cells. In particular, the A_{2A} AR decreases the functions of neutrophils, T cells activation, migration of mast cells and macrophages and the release of cytokines. The A_{2A} AR-mediated immune suppressive effect accounts for the profitable role of the A_{2A} stimulation in inflammatory processes. However, in some types of solid cancer, in which hypoxia enhances adenosine concentration, this effect can exacerbate. Hence, suppression of the immune responses in the tumor microenvironment, in particular those T cell-mediated, produces deleterious effects since protects cancer cells from death, thus promoting tumor growth and metastasis. As a consequence, A_{2A} AR antagonists, being effective in removing the adenosine-mediated immune escape, are considered as novel therapeutic agents in the immunotherapy of cancer.⁵

In the CNS, A_{2A} AR activation can exert opposite effects to the peripheral ones. The A_{2A} AR is present on both pre- and post-synaptic neurons and also in glial cells where it stimulates pro-inflammatory functions, particularly by inducing activation of both microglia and astrocytes in pro-inflammatory phenotype.^{1,4} Under physiological conditions, the A_{2A} AR expression in microglia and

1
2
3
4
5 astrocyte is usually low while it increases after brain insults, nerve injury and inflammatory
6
7 signals.^{6,7} Induction of glial A_{2A} AR expression takes part in an important feed-forward mechanism
8
9 to locally control neuroinflammatory responses in the brain.^{8,9} Activation of A_{2A} ARs in microglia
10
11 has mixed effects on proliferation of these cells, and clearly shows a facilitating action on the
12
13 release of pro-inflammatory cytokines, such as IL-1 β , TNF, IL-2 and IL-6, and of ROS, all
14
15 associated with neuronal damage occurring in Parkinson's (PD) and Alzheimer's (AD) diseases.⁹
16
17 Consequently, the blockade of the A_{2A} AR by antagonists induces neuroprotection in these CNS
18
19 disorders in which neuroinflammatory and oxidative processes play a significant role.¹⁻³
20
21 Neuroprotection attributed to A_{2A} AR antagonists have been associated also with their ability to
22
23 reduce glutamate levels by decreasing its release¹⁰⁻¹² and enhancing its glial uptake.^{6,13,14}
24
25
26
27 A_{2A} AR is also involved in the development of neuropathic pain and its blockade confers
28
29 protection.¹⁵ Neuropathic pain is a common type of chronic pain, which occurs in several disorders
30
31 and results in several factors leading to impairment in nerve function. Its pathophysiology is quite
32
33 complex and involves both central and peripheral mechanisms with alterations in the ion channel
34
35 expression, neurotransmitter release, and pain pathways.¹⁶ Although the molecular basis of
36
37 neuropathic pain is not completely understood, oxidative stress might contribute to its
38
39 development.¹⁷⁻¹⁹ In pain following spinal cord injury, beside dysfunction of neurons, other
40
41 pathogenic events occur, including microglia activation and enhanced extracellular glutamate
42
43 which, in turn, activates intracellular pathways such as ROS formation.²⁰ Platinum-based anticancer
44
45 drugs can cause peripheral neuropathy involving sensory nerves and it has been demonstrated that
46
47 the treatment with this kind of drugs induces, among others, ROS generation, damage at nuclear and
48
49 mitochondrial DNA, loss in antioxidant enzymes, and nerve tissue impairment.²⁰ In accordance,
50
51 systemic administration of antioxidant^{17,18} or ROS scavenger¹⁷ produces pain relief in different
52
53
54
55
56
57
58 animal model of neuropathic pain.
59
60


1
2
3
4
5 The role of the A_{2A} AR in pain is still controversial because several studies support both its pro- and
6 anti-nociceptive role, depending on the receptor localization and the type of pain.²¹ Coherent with a
7 pro-nociceptive role it was observed that after peripheral nerve injury, A_{2A} AR stimulation induces
8 both activation and proliferation of microglia and astrocytes responsible of inflammation occurring
9 in neuropathic pain, while genetic deletion of the A_{2A} AR decreases all the behavioral and
10 histological signs of pain.¹⁵ Several studies also showed that systemic^{22,23} and spinal²⁴
11 administration of the selective A_{2A} AR antagonist 2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-*e*]-
12 1,2,3-triazolo[1,5-*c*]pyrimidin-5-amine (SCH58261) produced antinociception in several preclinical
13 models. Moreover, potent hA_{2A} inverse agonists belonging to our thiazolo[5,4-*d*]pyrimidine series
14 showed an anti-nociceptive effect equal to or greater than morphine in acute pain models.²⁵
15
16 Taking into account these premises, over the last few years we have directed a part of our research
17 to obtaining new A_{2A} AR antagonists belonging to bicyclic²⁵⁻³³ and monocyclic³⁴ heterocyclic
18 classes. Among the former, the 8-amino-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazine-3-one series^{27,33}
19 was investigated and several potent hA_{2A} AR antagonists were identified, some of which proved to
20 be neuroprotective in PD²⁷ and AD³³ in vitro models. In this paper we describe new 1,2,4-
21 triazolo[4,3-*a*]pyrazines designed as hA_{2A} AR antagonists bearing an unsubstituted phenyl ring at
22 position 2 and different moieties at position 6 (**1-21**). The former group was chosen since it proved
23 to be an important feature to obtain an efficient hA_{2A} receptor-ligand interaction,²⁷ while the 6-
24 substituents were mostly selected to obtain dual acting antioxidant- A_{2A} AR antagonists. Compounds
25 endowed with this mixed activity have attracted our attention since they would possess a potentially
26 increased protective effect both in neurodegenerative diseases and in neuropathic pain. The new
27 triazolopyrazines can be subdivided into two sets, depending on the type of the 6-substituent.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



22 **Figure 1.** New 8-amino-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3-ones **1-11**.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

In the first set (**1-11**, Figure 1), derivatives **7-11** bear phenolic and polyphenolic rings at the 6-position. These kinds of substituents were chosen since they are a common feature of both natural and synthetic antioxidant agents. Among them, naturally occurring hydroxycinnamic acids, such as caffeic and ferulic acids, and resveratrol (Figure 2) were proven to exert diverse bioactivities affording neuroprotective effects.³⁵⁻³⁷ 3,5-Di-tert-butyl-4-hydroxytoluene (BHT) is a synthetic antioxidant used for food and pharmaceuticals.³⁷ Like other hindered phenols, BHT can exert biological functions for its ability to intercept and react with free radicals through atom transfer.³⁸



54 **Figure 2.** Some natural and synthetic antioxidant agents.

55
56
57
58
59
60

Considering our triazolopyrazines **7-11**, electron-donating groups were also introduced on the 6-(4-hydroxyphenyl) ring, in particular at the ortho position of the hydroxy group (Me, tert-But). These

substituents might have a role in improving radical scavenging activity, which may be mainly related to their ability to delocalize/stabilize the resulting phenoxyl radical.³⁷

The second set of triazolopyrazines (**12-21**, Figure 3) was synthesized to obtain derivatives **15-17**, **20**, **21**, in which antioxidant moieties were spaced by different linkers from the para position of the 6-phenyl ring.





Figure 3. New 8-amino-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3-ones **12-21**.

As antioxidant pendants, we selected α -lipoic and 3,5-di-tert-butyl-4-hydroxybenzoic acid residues. The latter was chosen for its structural similarity to BHT, the former because, besides being a naturally occurring compound present in food and used as dietary integrator, it emerged in preclinical studies as a promising agent for the treatment and/or prevention of neurodegenerative disorders.³⁹⁻⁴¹ At a molecular level, α -lipoic acid is effective in scavenging free radicals and reducing oxidative stress. It also increases or maintains cellular glutathione levels by acting as a transcriptional inducer of genes governing glutathione synthesis. Clinical studies investigating the effect of α -lipoic acid on diabetic neuropathy have revealed its efficacy in relieving neuropathic pain symptoms.^{42,43}

1
2
3
4
5 All the newly synthesized triazolopyrazines **1-21** were evaluated for their affinity at ARs. These
6 derivatives include not only the target compounds, bearing antioxidant moieties, but also their
7 synthetic precursors and some derivatives prepared to broaden SAR studies.
8
9
10

11 12 13 14 15 16 **RESULTS AND DISCUSSION**

17
18
19
20
21 **Chemistry.** The 1,2,4-triazolopyrazin-3-one derivatives **1-21** were prepared as depicted in Schemes
22 1-3. Compounds **1-11** (Scheme 1) were obtained starting from ethyl 5-oxo-1-phenyl-4,5-dihydro-
23 1*H*-1,2,4-triazole-3-carboxylate **22**⁴⁴ which was regioselectively N⁴-alkylated with the suitable α -
24 bromoketones **23-28**. Of the latter, **23-26** were previously reported,⁴⁵⁻⁴⁸ while **27** and **28** were newly
25 synthesized in the same conditions employed to obtain **23-26**, i.e. by brominating the corresponding
26 acetophenone derivatives **29** and **30**. Compound **29** was commercially available while **30** was
27 synthesized by methylation of (4-hydroxy-3,5-di-*tert*-butyl)phenylethanone.⁴⁹ The N₄-alkyltriazole
28 derivatives **31-36** were cyclized with ammonium acetate, by heating in a sealed tube, to give the
29 1,2,4-triazolo[4,3-*a*]pyrazine-3,8-dione derivatives **37-42** which were chlorinated with phosphorus
30 oxychloride, under microwave irradiation, to give the related 8-chloro derivatives **43-48**. Their
31 treatment with a saturated ethanolic solution of ammonia gave the desired 8-amino-1,2,4-
32 triazolo[4,3-*a*]pyrazine-3-one derivatives **1-6**. Reaction of the 6-(2,4-dimethoxy)phenyl derivative **1**
33 with BBr₃ 1M dichloromethane solution produced demethylation of the methoxy group at position
34 4, yielding to the 4-hydroxy-2-methoxyphenyl derivative **7**. Its structure was established by
35 NOESY experiment, indicating the spatial proximity between the methoxy group and the sole
36 aromatic proton at position 3.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 1^a


	R ₆		R ₆
1, 23, 31, 37, 43	C ₆ H ₄ -2,4-diOCH ₃	7	C ₆ H ₄ -2-OCH ₃ -4-OH
2, 24, 32, 38, 44	C ₆ H ₄ -3,4-diOCH ₃	8	C ₆ H ₄ -3,4-diOH
3, 25, 33, 39, 45	C ₆ H ₄ -3,4-OCH ₂ O	9	C ₆ H ₄ -3,4,5-triOH
4, 26, 34, 40, 46	C ₆ H ₄ -3,4,5-triOCH ₃	10	C ₆ H ₄ -4-OH-3,5-diCH ₃
5, 27, 35, 41, 47	C ₆ H ₄ -4-OCH ₃ -3,5-diCH ₃	11	C ₆ H ₄ -4-OH- tBu
6, 28, 36, 42, 48	C ₆ H ₄ -4-OCH ₃ -3,5-di-tBu		

^aReagents and conditions: (a) K₂CO₃, DMF/CH₃CN, rt; (b) Br₂, CHCl₃/Et₂O, 0 °C-rt; (c) CH₃I, K₂CO₃, 2-butanone, reflux; (d) NH₄OAc, 140 °C sealed tube; (e) POCl₃, mw 170 °C; (f) NH₃, absolute EtOH; (g) BBr₃, anhydrous CH₂Cl₂, 0 °C-rt.

Demethylation of the (methoxyphenyl) derivatives **2** and **4, 5** with BBr₃ (1M dichloromethane solution) gave the corresponding hydroxyphenyl-substituted compounds **8-10**. These conditions did

not work to demethylate the 6-(3,5-di-tert-butyl-4-methoxy)phenyl derivative **6**, probably due to the steric bulk of the two tert-butyl groups. Reaction was successful in more drastic conditions, i.e. with 48% aqueous HBr at reflux which, however, caused the removal of a tert-butyl substituent. Thus, the 3-tert-butyl-4-hydroxy derivative **11** was obtained, instead of the desired 4-hydroxy-3,5-di-tert-butyl derivative. Scheme 2 depicts the synthesis of the triazolopyrazines **12-16**, of which **15** and **16** were the target compounds linking antioxidant moieties.

Scheme 2^a




^aReagents and conditions: a) NC-CH₂-Cl or NH₂-CO-CH₂-Cl, K₂CO₃, anhydrous acetone, reflux; b) LiAlH₄, anhydrous THF, 0 °C; c) (R, S) lipoic acid or 3,5-di-tert-butyl-4-hydroxybenzoic acid, 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride, NEt₃, 1-hydroxybenzotriazole, anhydrous DMF, rt.

The starting material was the previously reported 6-(4-hydroxy)phenyl-triazolopyrazine **49**²⁷ which was O-alkylated with the suitable alkyl halides to give the corresponding 6-(4-O-alkylated)

compounds **12** and **13**. The cyano derivative **12** was reduced at rt with LiAlH_4 to afford the 6-(4-(2-aminoethoxy)phenyl) compound **14** which was reacted with (R,S) lipoic acid and 3,5-ditertbutyl-4-hydroxybenzoic acid, in anhydrous DMF and in presence of 1-hydroxybenzotriazole, 1-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride and triethylamine, to yield the desired derivatives **15** and **16**.

The synthesis of the triazolopyrazines **17-21** is shown in Scheme 3. The 6-(4-lipoylaminophenyl) derivative **17** was obtained by reacting the previously reported 6-(4-aminophenyl) derivative **50**³³ with (R,S) lipoic acid, in the same conditions described above to prepare **15** from **14**.

Scheme 3^a



^aReagents and conditions: a) (R, S) lipoic acid or 3,5-di-tert-butyl-4-hydroxybenzoic acid, 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride, NEt_3 , 1-hydroxybenzotriazole,

1
2
3
4
5 anhydrous DMF, rt; b) Cl-(CH₂)₂-COOH, 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide
6
7 hydrochloride, NEt₃, anhydrous DMF, rt; c) NH₃ gas/ absolute EtOH, sealed tube, 130 °C.
8
9

10
11
12
13 When the same experimental conditions were employed to react compound **50** with 3-
14 chloropropionic acid, the 6-(4-acrylamidophenyl) derivative **18** was obtained which was allowed to
15 react with a saturated solution of ammonia in absolute ethanol to afford the 6-(4-(3-
16 aminopropanamido)phenyl)-derivative **19**. This intermediate was transformed into derivatives **20**
17 and **21** by acylation with (R,S) lipoic acid and 3,5-ditertbutyl-4-hydroxybenzoic acid, respectively,
18 in the same conditions described above to obtain **15** from **14**.
19
20
21
22
23
24
25
26
27
28
29

30 **Binding and cAMP assays**


31
32 All the newly synthesized triazolopyrazines **1-21** were evaluated for their affinity at hA₁, hA_{2A} and
33 hA₃ ARs, stably transfected in Chinese hamster ovary (CHO) cells, and were tested at the hA_{2B} AR
34 subtype by determining their inhibitory effects on NECA-stimulated cAMP levels in hA_{2B} CHO
35 cells (Tables 1 and 2). Derivatives **11**, **12**, **15**, **20** and **21**, showing high hA_{2A} AR affinity and
36 selectivity, were selected to assess their antagonistic profile. Hence, their ability to inhibit or
37 stimulate the hA_{2A} AR was determined by evaluating their effect on cAMP production in CHO
38 cells, stably expressing hA_{2A} ARs (Table 3).
39
40
41
42
43
44
45
46
47
48
49
50

51 **Structure-Affinity Relationship Studies**





52
53 The results reported in Tables 1 and 2 displayed that several of the targeted triazolopyrazines
54 featuring potential antioxidant moieties (**7-8**, **10**, **11** and **15**, **17**, **20**, **21**) showed nanomolar hA_{2A}
55 AR affinity and different degrees of selectivity. Within the first set of compounds (Table 1), the 6-
56 (4-hydroxy-3-terbutyl)-phenyl derivative **11** was the most selective for the hA_{2A} AR (K_i= 8.5 nM).
57
58
59
60

The other phenolic derivatives (**7**, **8** and **10**) showed nanomolar affinity at the hA_{2A} AR, compound **10** being the most active ($K_i = 2.5$ nM), but scarce selectivity since they were able to bind the hA₁ subtype with significant affinity ($K_i = 21.3$ - 42.6 nM).

Table 1. Biological activity of compounds **1-11** at hARs.^a



	R ₆	Binding experiments			cAMP assays
		hA ₁ ^b	hA _{2A} ^c	hA ₃ ^d	IC ₅₀ (nM)
					hA _{2B} ^e
1		28 ± 0.3	2.4 ± 0.5	118 ± 6.6	>30000
2		59 ± 12.7	5.7 ± 0.8	80.1 ± 15.8	>30000
3		13 ± 2.5	7.4 ± 0.9	38 ± 6.7	>30000
4		55 ± 16	3.5 ± 0.8	214 ± 4.4	>30000
5		4.5 ± 1.4	0.17 ± 0.004	8.6 ± 1.7	>30000
6		108.5 ± 17	141.6 ± 34	>30000	>30000
7		29.7 ± 1.6	16.8 ± 0.9	11130 ± 975	> 30000

8		42.6 ± 9.6	5.2 ± 0.5	950 ± 200	>30000
9		175.5 ± 3	94.5 ± 21	5575 ± 989	17330 ± 3365
10		21.3 ± 7	2.5 ± 0.8	100 ± 0.7	>30000
11		>30000	8.5 ± 1.4	>30000	>30000


^aData (n= 3-5) are expressed as means ± standard errors. ^bDisplacement of specific [³H]-CCPA binding at hA₁ AR expressed in CHO cells. ^cDisplacement of specific [³H]-NECA binding at hA_{2A} AR expressed in CHO cells. ^dDisplacement of specific [³H]-HEMADO binding at hA₃ AR expressed in CHO cells. ^eIC₅₀ values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA_{2B} AR.

Derivatives **1-6**, including the methoxy synthetic intermediates and the 6-(3,4-methylenedioxyphenyl) derivative **3**, on the whole, showed high affinities for the hA_{2A} AR, spanning one-digit nanomolar values, and also for the hA₁ subtype. The most active compound at the hA_{2A} AR was derivative **5** (K_i= 0.17 nM), featuring the 6-(3,5-dimethyl-4-methoxyphenyl) substitution, while its 6-(3,5-di-tert-butyl-4-methoxyphenyl) analogue **6** showed significantly lower hA_{2A} AR binding activity (K_i= 141.6 nM), probably due to the steric bulk of the two tert-butyl groups. Compounds **5** and **3** also possess significant affinity for the hA₃ subtype.






In the second set of triazolopyrazines (**12-21**), α-lipoic acid and 4-hydroxy-3,5-ditertbutylbenzoic acid were selected as antioxidant portions and linked by different chains at the para position of the 6-phenyl ring. The choice of this position was based on the results of previous molecular docking

studies of this class of compounds at the hA_{2A} AR, highlighting that the presence of hindering substituents on the 6-phenyl ring favored a binding pose with this moiety pointing towards the extracellular side of the receptor. Hence, we envisaged that long substituents at the para position could be well tolerated because they could point away from the binding pocket. The selected chains were linked through an ethereal (compounds **15**, **16**) or an amide function (compounds **17**, **20** and **21**).

Table 2. Biological activity of derivatives **12-21** and the reference compounds **49** and **50**, at hARs.^a



	R	Binding experiments			cAMP assays
		hA ₁ ^b	hA _{2A} ^c	hA ₃ ^d	IC ₅₀ (nM)
					hA _{2B} ^e
12		> 30000	8.2 ± 2.3	> 30000	> 30000
13		391.7 ± 104	26 ± 1.7	604 ± 94	> 30000
14		288.7 ± 54	14.9 ± 0.1	2131 ± 173.5	> 30000
15		378.6 ± 91	2.4 ± 0.3	4097 ± 812	>30000
16		13670 ± 275	14750 ± 270	>30000	>30000

17		8.4 ± 0.4	5 ± 0.6	>30000	>30000
18		262.7 ± 1.9	1.8 ± 0.09	>30000	>30000
19		479.2 ± 89	0.59 ± 0.2	509 ± 90	9658 ± 1431
20		1359 ± 284	36.4 ± 8.2	>30000	>30000
21		>30000	54.5 ± 7.1	>30000	>30000
49 ^f	OH	45 ± 10	45 ± 12	53 ± 13	>30000
50 ^g	NH ₂	33.5 ± 6.7	22.9 ± 0.2	253.7 ± 67.6	>30000

^aData (n= 3-5) are expressed as means \pm standard errors. ^bDisplacement of specific [³H]-CCPA binding at hA₁ AR expressed in CHO cells. ^cDisplacement of specific [³H]-NECA binding at hA_{2A} AR expressed in CHO cells. ^dDisplacement of specific [³H]-HEMADO binding at hA₃ AR expressed in CHO cells. ^eIC₅₀ values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA_{2B} AR. ^fRef. 27. ^gRef. 33.

The binding data (Table 2) proved us right. On the whole, all the substituents appended on the 4-hydroxy- and 4-amino group of derivatives **49** and **50**, respectively, increased affinity and /or selectivity for the hA_{2A} AR (compare derivatives **12-16** to **49** and compounds **17-21** to **50**), with the only exception being compound **16**, which showed a dropped hA_{2A} AR binding activity.

The lipoyl derivatives **15**, **17** and **20** resulted in high affinity hA_{2A} AR ligands (K_i= 2.4-36.4 nM) with different degrees of selectivity versus the hA₁ AR, depending on the nature of the linker.

1
2
3
4
5 Compound **17**, bearing the lipoyl residue directly attached on the para-amino group, showed a high
6
7 affinity not only for the hA_{2A} receptor but also for the hA₁ AR subtype. Very interesting results
8
9 were obtained when the lipoyl moiety was spaced from the para-position through the flexible
10
11 oxyethylamino chain (-O-(CH₂)₂-NH-). In fact, the resulting compound **15** possessed a very high
12
13 affinity for the targeted hA_{2A} receptor (K_i= 2.4 nM) and also high selectivity, being significantly
14
15 less active at the hA₁ AR (K_i= 378.6 nM). When the oxyethylamino spacer was replaced by the
16
17 longer and more rigid carboxyamidoethylamino spacer (-NH-CO-(CH₂)₂-NH-), a selective ligand
18
19 for the hA_{2A} AR was still obtained (compound **20**) but its affinity and selectivity were lower, with
20
21 respect to those of **15**. The same two spacers were employed to link the (4-hydroxy-3,5-di-tert-
22
23 butyl)benzoyl pendant to the 6-phenyl ring (derivative **16** and **21**) but in this case an opposite effect
24
25 was obtained since the best results, both in terms of A_{2A} AR affinity and selectivity, were obtained
26
27 with the carboxyamidoethylamino spacer. In fact, compound **21** showed good affinity for the hA_{2A}
28
29 AR (K_i= 54.5 nM) and high selectivity, while its analogue **16** was almost inactive at all ARs. The
30
31 significant difference between hA_{2A} affinities of the two compounds obviously depends on the
32
33 different spacer. The bit longer carboxyamidoethylamino spacer seems to direct the terminal bulky
34
35 aryl ring in a more favorable pose in the receptor binding site (see modeling analysis). Also
36
37 derivatives **12-14** and **18, 19**, which were not our primary target compounds, resulted in interesting
38
39 ligands, showing nanomolar affinity and good to high selectivity for the hA_{2A} AR. In particular,
40
41 derivative **19**, bearing the carboxyamido-ethylamine substituent at the para position of the 6-phenyl
42
43 ring, was the most active (K_i= 0.59 nM). Derivatives **12** and **18**, featuring at the para-position a
44
45 cyanomethoxy (K_i= 8.2 nM) and an acrilamido group (K_i= 1.8 nM), respectively, displayed high
46
47 hA_{2A} AR affinities and selectivity. Reduction of the cyano residue of compound **12** afforded the
48
49 amino derivative **14** which maintained the ability to target the hA_{2A} AR with nanomolar affinity
50
51 (K_i= 14.9 nM) but lower selectivity. Transformation of the cyano in amide group (compound **13**)
52
53 also retained affinity but reduced selectivity for the target hA_{2A} receptor.
54
55
56
57
58
59
60

1
2
3
4
5 Finally, compounds **11**, **12**, **15**, **20** and **21**, showing high hA_{2A} AR affinity and selectivity, were
6
7 selected to be further pharmacologically profiled in *in vitro* studies. Previously, we ascertained their
8
9 antagonistic profile by evaluating their effect on cAMP production in CHO cells, stably expressing
10
11 hA_{2A} ARs (Table 3). The compounds proved to be able to counteract NECA-stimulated cAMP
12
13 production, thus behaving as hA_{2A} AR antagonists.
14
15
16
17
18

19 **Table 3.** Potencies of the selected triazolopyrazines **11**, **12**, **15**, **20** and **21** at hA_{2A} AR.
20

	hA _{2A} AR (IC ₅₀ nM) ^a
11	179 ± 53
12	157 ± 43
15	116 ± 31
20	296 ± 66
21	263 ± 58

21
22
23
24
25
26
27
28
29
30
31
32
33 ^aIC₅₀ values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing
34
35 hA_{2A} AR. Data are expressed as means ± standard errors.
36
37
38
39

40 **Molecular modeling studies.** The binding mode of the synthesized compounds at the hA_{2A} AR
41
42 cavity was simulated with docking analysis by using the MOE (Molecular Operating Environment
43
44 2014.09) software and the CCDC Gold docking tool.^{50,51} The MOE software analysis was carried
45
46 out by selecting the induced fit docking and optimization protocol (schematically, a preliminary
47
48 docking analysis providing a set of ligand conformations then energy minimized with the side
49
50 chains of the receptor residues in proximity). For the docking tasks, a crystal structure of the hA_{2A}
51
52 AR in complex with the antagonist/inverse agonist ZM241385 was employed (<http://www.rcsb.org>;
53
54 pdb code: 5NM4; 1.7-Å resolution⁵²). For a subset of compounds, the binding modes at the hA₁ AR
55
56 crystal structure (pdb code: 5N2S; 3.3-Å resolution⁵³) were also simulated with the same tools and
57
58
59
60 protocols.

1
2
3
4
5 The docking conformations generally obtained for the new derivatives at the hA_{2A} AR are similar to
6 those observed for our previously reported triazolopyrazines and is shown in Figure 4A.²⁷ In this
7 binding mode, the bicyclic core is positioned between the side chains of Phe168 (EL2) and
8 Leu249^{6,51} and engages non-polar interactions with these residues. The exocyclic amine group
9 makes H-bond contacts with Asn253^{6,55} and Glu169 (EL2), while the 2-phenyl substituent is
10 located in the depth of the cavity. The R₆ group is positioned at the entrance of the binding site and
11 oriented toward the extracellular environment. Such compound orientation and interaction resemble
12 the binding mode of the co-crystallized 4-(2-[7-amino-2-(2-furyl[1,2,4]-triazolo[2,3-
13 *a*][1,3,5]triazin-5ylamino]ethyl)phenol (ZM241385) in the employed crystal structure⁵² but also in
14 other previously reported hA_{2A} AR X-ray structures.^{54,55}

15
16
17
18
19
20
21
22
23
24
25
26
27
28 The presence of substituents on the 6-phenyl ring modulates the interaction with the receptor
29 residues at the entrance of the cavity and leads to various degrees of affinity for the hA_{2A} AR (see
30 Tables 1 and 2). For previously reported analogues,²⁷ it was observed that a non-polar para-
31 substituent on this ring was more efficient to improve the hA_{2A} AR affinity than a polar one.
32 Considering the meta-substituents of the 6-phenyl ring, the affinity data showed that the hA_{2A} AR
33 affinity was not significantly influenced by the chemical-physical profile of the substituent.
34 Compounds of this new set of triazolopyrazines, differing in polarity of para- or meta-substituent,
35 present various hA_{2A} AR affinity. Considering derivatives bearing a small 4-substituent on the 6-
36 phenyl moiety, again a non-polar para-substituent on this ring appears more efficient to improve the
37 hA_{2A} AR affinity than a polar one. As an example, compounds **5**, the most active of the herein
38 reported derivatives, featuring a 4-methoxy and 3,5-di-methyl groups on the 6-phenyl ring, is
39 endowed with 15-fold higher affinity at the hA_{2A} AR than **10**, which bears a 4-hydroxy and 3,5-di-
40 methyl groups.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 4. (A) General binding mode of the synthesized compounds at the hA_{2A} AR (pdb: 5NM4) binding cavity, with indication of some key receptor residues; compound **5** is showed. (B) Top-view of the hA_{2A} AR residues at the entrance of the binding cavity and potentially giving interaction with substituents on the 6-phenyl ring. (C) Molecular surface representation of the entrance of the hA_{2A} AR binding cavity; dark-to-light color indicates hydrophilic-to-hydrophobic scale.

The substituents inserted on the 6-phenyl ring are located in proximity of Ile66^{2,64}, Ser67^{2,65}, Leu167 (EL2), Leu267 (EL3), Met270^{7,35} and Tyr271^{7,36} (Figure 4B-C). Considering the volume, Figure 4C shows a molecular surface representation of the entrance of the hA_{2A} AR binding cavity. From this figure it can be seen that small substituents are allowed in the ortho- and meta-position of the R₆ group, but the space is too limited to allow the insertion of two or more bulky moieties at the same positions. In fact, compound **6**, bearing two tert-butyl groups at the meta-position of the 6-phenyl ring, has a significantly reduced hA_{2A} AR affinity compared to the other analogues (Table 1). The non-polar profile of the above cited amino acids surrounding the R₆ group allows a

1
2
3
4
5 favorable interaction with non-polar substituents rather than polar ones. Combinations of para- and
6
7 meta-substituents or para- and ortho-substituents lead to slight modulation of hA_{2A} AR affinity.
8
9



40 **Figure 5.** (A) General binding mode of the synthesized compounds at the hA₁ AR (pdb: 5N2S)
41 binding cavity, with indication of some key receptor residues; compound **19** is shown. (B) Top-
42
43 view of the hA₁ AR residues at the entrance of the binding cavity and potentially giving interaction
44
45 with substituents on the R₆ aryl ring.
46
47
48
49

50
51 Docking results obtained at the hA₁ AR crystal structure are highly similar to the ones obtained at
52
53 the hA_{2A} AR (Figure 5). Considering compounds bearing small substituents at the meta- and para-
54
55 position of the 6-phenyl group, docking conformations suggest analogue considerations as above
56
57 for the impact on the hA₁ AR affinity given by these substituents. This is in agreement with
58
59 biological evaluation results of compounds **1-5,7-10**, which show similar trends of binding affinity
60

1
2
3
4
5 values at hA₁ AR and hA_{2A} AR. As for the hA_{2A} AR, compound **5** is the most active of the whole set
6
7 of derivatives at the hA₁ AR, with 4-fold higher affinity than **10**, its para-hydroxy substituted
8
9 analogue. Even in this case, compounds bearing tert-butyl groups are endowed with lower affinity.

11 Still considering compounds bearing small substituents at the meta- and para-position of the R₆
12
13 group, affinities at the hA_{2A} AR are generally higher than those observed at the hA₁ AR. The set of
14
15 hA_{2A} AR residues in proximity with the para-substituent is globally more hydrophobic than the hA₁
16
17 AR one, due to the presence of Leu167 (EL2), Leu267 (EL3), Met270^{7,35} in the hA_{2A} AR instead of
18
19 the Glu170 (EL2), Ser267 (EL3) and Thr271^{7,35} residues in the respective positions of the hA₁ AR.
20
21 This factor could play a key role in providing a slight hA_{2A} AR selectivity (versus the hA₁ AR) for
22
23 the compounds described above.
24
25
26

27
28 Considering the compounds presenting only small para-substituents on the 6-phenyl ring (**12-14**,
29
30 **18, 19**), the hA_{2A} AR affinities appear significantly higher than the hA₁ AR ones. The different
31
32 affinity for the two AR subtypes could be due to both the chemical-physical profile of the AR
33
34 residues in proximity of the substituent and how much the substituent itself is exposed to the
35
36 external environment. Figure 6A-B shows a surface representation of the entrance of the binding
37
38 cavities, in proximity to the para-position of the 6-phenyl ring. The light-to-dark regions indicate a
39
40 hydrophobic-to-hydrophilic profile of the residues. The more polar profile of the hA₁ AR residues
41
42 with respect to the hA_{2A} AR ones is due in particular to the presence of a negatively charged
43
44 glutamate residue (Glu170, Figure 5B) in hA₁ AR, while the hA_{2A} AR bears a non-polar leucine
45
46 (Leu167, Figure 4B) in the same position. The presence of Glu170 in hA₁ AR leads to a repulsive
47
48 effect between this residue and the carbonyl group of the compounds bearing a carboxyamidoethyl
49
50 spacer (**19, 20, 21**). This effect is evident from the comparison of the activities of the latter
51
52 compounds with the higher affinity data at the hA₁ AR of the corresponding analogues bearing an
53
54 oxyethyl spacer (**14, 15, 16**, respectively). At the hA_{2A} AR, both the carboxyamidoethyl and
55
56 oxyethyl spacers generally lead to nanomolar affinities.
57
58
59
60




Figure 6. A-B Top-view of the binding mode of compound **19** at the hA_{2A} AR (A, pdb: 5NM4) and hA₁ AR (B pdb: 5N2S) binding sites. Molecular surface representations of both binding cavities are represented. Light-to-dark colors of surface correspond to hydrophobic-to-hydrophilic regions. C-D. Binding modes suggested for compounds bearing large para-substituents in the 6-phenyl ring; compound **15** at the hA_{2A} AR (pdb: 5NM4) is shown. These molecules may adopt the general binding mode above described (C) or an alternative, energetically more stable, docking conformation that makes the para-substituent externally oriented without clashes with receptor residues (D).

Docking studies performed for the compounds presenting small para-substituents (**12-14**, **18**, **19**) show that these molecules may adopt a binding mode similar to the one described above. The

1
2
3
4
5 interaction of the para-substituent with hA_{2A} AR residues is modulated by the chemical-physical
6 profile of the substituent itself and the receptor residues in proximity. The positively charged amine
7 function of compound **19** gets located in proximity of both the hydroxyl group of Tyr271^{7,36} and the
8 carbonyl group of Ser67^{2,65} (Figures 4B and 6A), thus providing subnanomolar affinity for the hA_{2A}
9 AR. Compounds bearing a large para-substituent (**15-17**, **20-21**) may adopt as well as the above-
10 described binding mode (Figure 6C, compound **15**), even if the large para-substituent gets located
11 too close to the receptor residues, giving a steric clash with the protein atoms. Docking results for
12 these compounds suggest also an alternative binding mode, with the bicyclic scaffold upside-down
13 oriented to point the 3-carbonyl group toward the amine function of Asn253^{6,55} (Figure 6D,
14 compound **15**). This binding mode lacks some hydrophilic interactions with the receptor that are
15 observed in the general compound orientation described above (i.e. with Glu169 at hA_{2A} AR); on
16 the other hand, the alternative binding mode favors the pointing of the para-substituent toward the
17 external environment with a more energetically stable compound conformation. This may explain
18 the favorable docking scores obtained by the alternative binding mode arrangement for compounds
19 bearing large para-substituents in the 6-phenyl ring. Considering the largest compounds (**15**, **16**, **20**,
20 **21**), the lowest activity belongs to derivative **16**, which is the one presenting a para-substituent of
21 large volume and the shortest oxyethylamino spacer linking the 6-phenyl ring. In contrast, its
22 corresponding analogue with the longer carboxyamidoethyl spacer (**21**) presents a 300-fold
23 improvement of the hA_{2A} AR affinity. On the other hand, both derivatives presenting a less bulky
24 lipoyl group (**15** and **20**) are endowed with significantly higher affinity. This suggests that the
25 length and volume of the large para-substituents appear critical for the receptor affinity, for an
26 energetically stable accommodation of the substituent itself within the receptor residues.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **Neuroprotection Studies on oxaliplatin-induced neurotoxicity in microglia cells.** Based on the
58 affinity data, compounds **11**, **12**, **15**, **20** and **21**, potent and selective hA_{2A} AR antagonists, were
59
60

1
2
3
4
5 selected for further pharmacological evaluation. In particular, their protective effect against the
6
7 neurotoxicity of the anticancer drug oxaliplatin on rat microglia cells was determined. Neuropathy
8
9 induced by oxaliplatin is a common side effect in patients treated with this drug and consists in
10
11 paresthesia, dysesthesia, and pain. Such a condition adversely affects quality of life and can lead to
12
13 discontinuation of therapy.⁵⁶ It is well-known that glia cells play a key role in the CNS homeostasis
14
15 and are strongly involved in the responses to nerve injury. Microglia and astrocytes activate several
16
17 mechanisms, such as production of trophic factors, regulation of transmitter and ion concentrations,
18
19 which tend to decrease neuronal injury. Nevertheless, in pathological conditions, the maladaptive
20
21 plasticity of glial cells strongly sustains negative symptoms like chronic pain. In particular,
22
23 microglia functional modifications have the potential to induce neuronal dysfunction, playing a
24
25 pivotal role in oxaliplatin neuropathy development.^{57,58}

26
27
28
29
30 The selected compounds were chosen taking into account their high affinity and selectivity toward
31
32 the hA_{2A}AR but also the presence in all of them, except compound **12**, of antioxidant moieties
33
34 which were thought to counteract oxaliplatin neurotoxicity. In fact, although the molecular basis
35
36 underlying the oxaliplatin neuropathy is unclear, some experimental evidence pointed out a
37
38 correlation between oxidative stress damage and neuropathic pain onset,²⁰ also highlighting efficacy
39
40 of the antioxidant silibinin and α -tocopherol in reducing oxaliplatin-dependent pain induced by
41
42 mechanical and thermal stimuli.⁵⁹ Compound **12**, lacking the antioxidant portion, was tested to
43
44 evaluate how the lone blockade of the A_{2A} AR could affect oxaliplatin toxicity.

45
46
47
48 Primary rat microglia cells were treated with oxaliplatin in the absence or in the presence of the
49
50 tested compounds. Oxaliplatin damage was evaluated as cell viability and oxidative stress, the latter
51
52 previously described as the main damage evoked by oxaliplatin.⁶⁰ The new synthesized compounds
53
54 were tested at 10 μ M, the maximum soluble concentration. Oxaliplatin, concentration-dependently,
55
56 strongly reduced microglia viability (MTT test) after 24 h incubation (33% and 19% viability with
57
58 10 and 30 μ M, respectively, in comparison to 100% of control condition).
59
60

The obtained results showed that the lipoic acid-conjugated derivative **15** was the most active in preventing the oxaliplatin damage, also when incubated at the high oxaliplatin concentration (30 μM). Compound **12** was instead effective against 10 μM oxaliplatin. Regarding the other tested compounds, the 6-phenol derivatives **11** and **21** showed partial activity at both oxaliplatin concentrations, whereas the lipoic derivative **20**, contrary to our expectations, turned out to be ineffective (Table 4). This latter result might be due to a possible instability of **20** in the microglia assay medium, as reported in the “Chemical stability study” section.

Table 4. Compound effects on microglial cell viability^a

	Cell viability (%)		
	Oxa 0 μM	Oxa 10 μM	Oxa 30 μM
Control	100.0 \pm 7	33.2 \pm 1.3**	19.1 \pm 0.8**
DMSO 0.75%	90.9 \pm 8		
11 10 μM		46.4 \pm 1.4^^	28.6 \pm 1.21^
12 10 μM		48.7 \pm 0.8^^	23.0 \pm 0.9
15 10 μM		54.5 \pm 1.9^^	34.2 \pm 0.60^
20 10 μM		38.9 \pm 1.6	18.3 \pm 0.3
21 10 μM		43.5 \pm 1.8^	30.6 \pm 2.2^

^a Primary rat microglia cells were plated 4000 cells/well and 24 hours later cells were treated with oxaliplatin (Oxa) 10 and 30 μM in presence of **11**, **12**, **15**, **20** and **21** at 10 μM for 24 hours. Cell vitality was assessed via MTT assay. Viability is expressed as % in comparison to the control cells (arbitrarily set 100% of viable cells). Data are presented as mean \pm SEM of three experiments.

*P<0.05 and **P<0.01 versus control; ^P<0.05 and ^^P<0.01 versus oxaliplatin.

Further investigations were carried out on these compounds by evaluating their ability to prevent the oxaliplatin-dependent increase of the SOD-inhibitable superoxide anion (cytochrome C assay). According to the obtained data, compounds **15** and **21** proved to be effective in significantly

decreasing the oxygen free radical level thus suggesting a direct antioxidant activity or, hypothetically, a protective property against mitochondrion (Figure 7).




Figure 7. Compound effects on SOD-inhibitable O₂⁻ concentrations in rat microglia cells. Microglia cells (5×10^5 cells/well) were exposed to 100 μM oxaliplatin for 4h in the absence or presence of tested compounds (10 μM). O₂⁻ concentration was evaluated by cytochrome *c* assay. The nonspecific absorbance was measured in the presence of SOD (300 mU/ml) and subtracted from the total value. Values are expressed as the mean \pm SEM of three experiments. *P<0.05 and **P<0.01 versus control; ^P<0.05 and ^^P<0.01 versus oxaliplatin.

The activity of the detoxifying enzyme catalase was also measured to study the potential effect of new compounds on peroxisomes, the other intracellular organelle involved in the redox balance. As shown in Figure 8, oxaliplatin impaired peroxisome functionality, reducing catalase activity while **15** and **21** significantly prevented the damage.




Figure 8. Compound effects on catalase activity. Microglia cells ($5 \cdot 10^5$ cells/well) were treated with oxaliplatin ($10 \mu\text{M}$) in the absence or in the presence of the new compounds ($10 \mu\text{M}$). Activity was measured after 24h incubations. Values are expressed as the mean \pm S.E.M. of three experiments. Control condition was arbitrarily set as 100%. * $P < 0.05$ and ** $P < 0.01$ versus control; $^{\wedge}P < 0.05$ and $^{\wedge\wedge}P < 0.01$ versus oxaliplatin.

Behavioral studies in the oxaliplatin-induced neuropathy model. On the basis of the results obtained from in vitro tests, we selected compounds **12**, **15** and **21** for an in vivo study in a mouse model of oxaliplatin-induced neuropathy. On day 14, after a repeated treatment with the anticancer drug injected at a clinically-relevant dose,⁶¹ the hypersensitivity to a cold non noxious stimulus (cold plate test) was significantly established (Figure 9). The pain-relieving effects of new synthesized compounds were tested after a single per os administration. Compounds **12** and **21** (10 and 30 mg kg^{-1}) were able to increase the pain threshold between 15 and 45 min after treatment. Interestingly, compound **15** induced significant relieving effects starting from the 0.03 mg kg^{-1} dose. The efficacy, dose-dependently, increased till it completely reverted oxaliplatin-induced neuropathic

pain when administered at 1 and 10 mg kg⁻¹. The effect of **15** began 30 min after treatment, and the compound was still fully active at 60 min. In the same model, lipoic acid, administered per os at an equimolar dose (4 mg kg⁻¹) to 10 mg kg⁻¹ of compound **15**, was completely inactive. Also when tested at 10-fold higher dose (40 mg kg⁻¹), lipoic acid was ineffective (Figure 9).




Figure 9. Compound effects against neuropathic pain. Mice were repeatedly treated with oxaliplatin (2.4 mg kg⁻¹; dissolved in 5% glucose solution and i.p. administered). On day 14, compounds were suspended in carboxymethylcellulose and administered p.o. Pain-related behavior (i.e. lifting and licking of the hind paw) was observed and the time (in seconds) of the first sign was recorded. **P<0.01 vs vehicle + vehicle treated animals; ^P<0.05 and ^^P<0.01 vs oxaliplatin + vehicle treated animals. Each value represents the mean of 10 mice performing in two different experimental sets.

The significant difference between the potency of the lipoic-conjugated triazolopyrazine **15** and lipoic acid could be due both to diverse pharmacokinetic properties of the two compounds and to the presence of the hA_{2A} AR antagonist component in derivative **15**. This hypothesis is supported by data obtained in different animal model of neuroprotection^{37,59,60} indicating that lipoic acid is well absorbed per os but is subject to pre-systemic elimination by the liver, and in rat only about 27-34% lipoic acid administered orally is available for absorption by the tissue.⁵⁹ Moreover, the complexity of neuropathic pain signaling does not allow consideration of the redox imbalance as the unique pathological signature.⁵⁴ The importance of the hA_{2A} AR antagonist component in reducing oxaliplatin-induced neuropathy is underlined by the pain-relieving effect of compound **12**, lacking the antioxidant portion. It is worth noting that the lipoic-conjugated compound **15**, showing the best activity in the microglia assays, was the most active also in this in vivo model. Hence, we hypothesized that these findings might be ascribed, at least in part, to the higher affinity of compound **15** for the A_{2A} AR in rodents, with respect to those of **12** and **21**, as could be envisaged on the basis of the A_{2A} AR affinities obtained for the human species (Table 2). To confirm our prediction, binding studies at the rat (r) A_{2A} AR were carried out on the three derivatives. The achieved results (Table 5) confirmed the expected trend, because the lipoic derivative **15** displayed the highest binding value, being about 4-fold and 10-fold more active than compounds **12** and **21**, respectively.

Table 5. Binding activity of compounds **12**, **15**, **21**, and ZM241385 as reference ligand, at rA_{2A} AR.^a

	rA _{2A} K _i nM ^b
12	39 ± 5.6
15	9 ± 1.7
21	86 ± 9.1
ZM241385	2.8 ± 0.3

^aData (n= 3-5) are expressed as means \pm standard errors. ^bDisplacement of specific [³H]-NECA binding at rA_{2A} AR expressed in CHO cells.

Obviously, besides the different rA_{2A} AR affinity, other molecular features, such as the antioxidant character and the pharmacokinetic properties, can be responsible of the diverse in vivo activity of these triazolopyrazines. The higher potency of derivative **15**, compared to **21**, suggests that the lipoic acid residue, with respect to the BHT-analogue group, might confer enhanced in vivo properties, for both its antioxidant activity and its positive effect on pharmacokinetics. To address this issue further studies have been planned to gain more insight into the interesting protective profile of compound **15**.

Chemical stability study. Compounds **11**, **12**, **15**, **20** and **21**, selected for pharmacological evaluation, feature antioxidant moieties, amide functions, or a cyano group. All these functionalities might have some lability, hence we thought it interesting to ascertain their stability towards spontaneous or enzymatic degradation in 50 mM tris(hydroxymethyl)aminomethane hydrochloride buffer solution (50 mM Tris buffer, pH= 7.4) and human plasma, respectively.

The instrumental conditions are reported in the Experimental Procedure section.

The solution stability of each studied compound was verified by monitoring the variation of its concentration at different incubation times in 50 mM Tris buffer and human plasma samples. By plotting these data (natural logarithm of analyte concentration versus the incubation time) the respective degradation profiles were obtained (Figures 10 and 11 and Figures 1S-4S in Supporting Information) which demonstrated that all the compounds were stable in 50 mM Tris buffer and most of them also in human plasma. In fact, only the degradation plots of the 6-(3-ter-butyl-4-hydroxyphenyl) derivative **11** and the lipoyl derivative **20** (Figures 10 and 11) in human plasma

1
2
3
4
5 showed a significant decay rate (k value, defined in Supporting Information) and their calculated
6
7 half-life values ($t_{1/2}$) are 122 ± 4 min and 41 ± 13 min respectively, as displayed in Table 4.
8
9
10
11
12




Figure 10. Degradation plots of compound **11** in 50 mM Tris buffer solution (blue square) and human plasma (red triangle).




Figure 11. Degradation plots of compound **20** in 50 mM Tris buffer solution (blue square) and human plasma (red triangle).

The half-life value of ketoprofene ethylester (KEE), used as reference compound, demonstrated that the employed human batch was enzymatically active (half-life < 2 h).⁶⁴ The k values of the stable compounds were close to 0; consequently for these derivatives, extremely high $t_{1/2}$ values can be calculated. Since under the proposed experimental conditions a half-life over 240 min is not correctly evaluated, it is reasonable to consider that their half-life values could be equal to or greater than 240 min. The 50 mM Tris buffer and human plasma half-lives of other studied compounds are reported in Table 5.

Table 5. Half-life ($t_{1/2}$) of studied compounds in 50 nM Tris buffer and human plasma samples.

50 mM Tris buffer	Human-plasma
$t_{1/2} \pm \text{error (min)}$	$t_{1/2} \pm \text{error (min)}$

KEE	nd ^a	107 ± 16
11	≥240	122 ± 4
12	≥240	≥240
15	≥240	≥240
20	≥240	41 ± 13
21	≥240	≥240

^anot determined

To summarize, these experiments demonstrated that the tested compounds did not suffer significant degradation process under the proposed conditions. Only derivatives **11** and **20** showed a clear degradation rate in human plasma, but with large different of $t_{1/2}$ values (122 ± 4 and 41 ± 13 respectively). The behavior of **20** might suggest a possible explanation of its inactivity on microglia cell viability test, where all the other compounds proved to be effective. Hence, inactivity of **20** might be partly ascribed to its possible decomposition in the microglia assay medium.

CONCLUSION

This study has produced new highly potent and selective antagonists for the hA_{2A} AR, some of which possess hindering antioxidant functions. Insertion of these functions on the 6-aryl group, notwithstanding their high steric bulk, maintained a nanomolar hA_{2A} AR affinity and high selectivity. Molecular docking studies highlighted that the 6-aryl moiety of these new triazolopyrazines is positioned at the entrance of the hA_{2A} AR binding site and that both lipophilicity and the volume of the substituent inserted on this ring modulate affinity and selectivity. On the whole, non-polar para-substituents are more efficient than polar groups in improving hA_{2A} receptor-ligand interaction due to the presence of non-polar amino acid residues surrounding the 6-aryl pendant. Further pharmacological studies were carried out on selected triazolopyrazines showing high hA_{2A} affinity and selectivity. Compounds **11**, **15** and **21**, featuring antioxidant

1
2
3
4
5 moieties, and compound **12**, lacking the antioxidant functionality, reduced oxaliplatin-induced
6
7 toxicity in microglia cells, the most active being the lipoyl derivative **15**. This compounds and, to a
8
9 lesser extent, the BHT analogue **21** proved to be effective in reducing the oxygen free radical level,
10
11 thus suggesting a direct antioxidant activity. Derivatives **12**, **15** and **21**, further investigated in vivo,
12
13 were able to reduce oxaliplatin-induced neuropathy in mouse. Also in these tests, the lipoyl-
14
15 derivative **15** displayed the best results, being able to completely revert oxaliplatin-induced pain
16
17 when administered at 1 and 10 mg kg⁻¹. The in vivo efficacy of derivative **15** makes it a promising
18
19 neuroprotective candidate in oxidative stress-related pathologies.
20
21
22
23
24

25 **EXPERIMENTAL PROCEDURE**

26
27 **Chemistry.** The microwave-assisted syntheses were performed using an Initiator EXP Microwave
28
29 Biotage instrument (frequency of irradiation: 2.45 GHz). Analytical silica gel plates (0.20 mm,
30
31 F254, Merck, Germany) and silica gel 60 (Merck, 70-230 mesh) was used for analytical and column
32
33 chromatography, respectively. All melting points were determined on a Gallenkamp melting point
34
35 apparatus and are uncorrected. Elemental analyses were performed with a Flash E1112
36
37 Thermofinnigan elemental analyzer for C, H, N and the results were within 0.4% of the theoretical
38
39 values. All final compounds revealed purity not less than 95%. The IR spectra were recorded with a
40
41 Perkin-Elmer Spectrum RX I spectrometer in Nujol mulls and are expressed in cm⁻¹. NMR spectra
42
43 were recorded on a Bruker Avance 400 spectrometer (400 MHz for ¹H- and 100 Mz for ¹³C- NMR).
44
45 The chemical shifts are reported in δ (ppm) and are relative to the central peak of the solvent which
46
47 was CDCl₃ or DMSOd₆. The following abbreviations are used: s= singlet, d= doublet, t= triplet, q=
48
49 quartet, m= multiplet, br= broad and ar= aromatic protons. The high resolution mass spectrometry
50
51 (HRMS) analysis was performed with a Thermo LTQ Orbitrap mass spectrometer equipped with an
52
53 electrospray ionization source (ESI). The analysis were carried out in positive ion mode monitoring
54
55 the [M+H]⁺ species by using a proper dwell time acquisition to achieve 60,000 resolving power
56
57
58
59
60

1
2
3
4
5 units at Full Width at Half Maximum of the m/z signal. Elemental composition of compounds were
6
7 calculated on the basis of their measured accurate masses, accepting only results with an attribution
8
9 error less than 5 ppm and a not integer double bond/ring equivalents value, in order to consider only
10
11 the protonated species.⁶⁵

12
13
14 Compounds were named following IUPAC rules as applied by ChemDrawUltra 9.0.

15
16
17
18
19 **General procedure for the synthesis of 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-**
20
21 **3(2*H*)-ones (1-6).** A suspension of the 8-chloro-triazolopyrazine derivatives **43-48** (1.0 mmol), in a
22
23 saturated ethanolic solution of NH_3 (50 mL), was heated at 140 °C in a sealed tube for 16 h. The
24
25 mixture was cooled at rt, the suspended solid was collected by filtration, washed with water (about
26
27 5-10 mL), and purified by recrystallization or column chromatography.

28
29
30
31
32 **8-Amino-6-(2,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3 (2*H*)-one (1).** Yield
33
34 43%; mp 255-257 °C (EtOH/2-methoxyethanol). ^1H NMR ($\text{DMSO-}d_6$) 8.07 (d, 2H, ar, $J = 8.4$ Hz),
35
36 8.02 (d, 1H, ar, $J = 8.6$ Hz), 7.80 (s, 1H, H-5), 7.57 (t, 2H, ar, $J = 8.4$ Hz), 7.43 (br s, 2H, NH_2), 7.35
37
38 (t, 1H, ar, $J = 7.4$ Hz), 6.64-6.68 (m, 2H, ar), 3.92 (s, 3H, CH_3), 3.82 (s, 3H, CH_3). Anal. Calcd for
39
40 $\text{C}_{19}\text{H}_{17}\text{N}_5\text{O}_3$: C, 62.80; H, 4.72; N, 19.27. Found: C, 62.67; H, 4.68; N, 19.36. ESI-HRMS (m/z)
41
42 calculated for $[\text{M}+\text{H}]^+$ 364.1404, found 364.1409.

43
44
45
46 **8-Amino-6-(3,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2*H*)-one (2).** Yield
47
48 65%; mp 212-214 °C (EtOH/2-methoxyethanol). ^1H NMR ($\text{DMSO-}d_6$) 8.08 (d, 2H, ar $J = 7.7$ Hz),
49
50 7.76 (s, 1H, H-5), 7.52-7.58 (m, 5H, 3ar + NH_2), 7.36 (t, 1H, ar, $J = 7.4$ Hz), 7.00 (d, 2H, ar, $J = 8.4$
51
52 Hz), 3.86 (s, 3H, OCH_3), 3.80 (s, 3H, OCH_3). ^{13}C -NMR ($\text{DMSO-}d_6$) 149.42, 149.20, 147.63,
53
54 137.99; 135.92, 131.54, 129.64, 129.57, 126.72, 119.85, 118.63, 112.05, 109.59, 100.99, 56.09,
55
56 55.98. IR 3348, 3340-3300, 1714, 1699. Anal. Calcd for $\text{C}_{19}\text{H}_{17}\text{N}_5\text{O}_3$: C, 62.80; H, 4.72; N, 19.27.

1
2
3
4
5 Found: C, 62.98; H, 4.83; N, 19.45. ESI-HRMS (m/z) calculated for $[M+H]^+$ 364.1404, found
6
7 364.1407.

8
9 **8-Amino-6-(3,4-methylenedioxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one (3).**

10
11 Yield 96%; mp > 300 °C (AcOH/DMF). ^1H NMR (DMSO- d_6) 8.07 (d, 2H, ar, J = 7.8 Hz), 7.72 (s,
12
13 1H, H-5), 7.54-7.58 (m, 6H, 4ar + NH₂), 7.35 (t, 1H, ar, J = 7.4 Hz), 6.96 (d, 1H, ar, J = 7.9 Hz),
14
15 6.06 (s, 2H, CH₂). ^{13}C -NMR (DMSO- d_6) 148.12, 147.67, 147.63, 147.60, 137.97, 135.62, 131.54,
16
17 131.09, 129.65, 126.74, 119.92, 119.86, 108.63, 106.26, 101.58, 101.09. Anal. Calcd for
18
19 C₁₈H₁₃N₅O₃: C, 62.24; H, 3.77; N, 20.16. Found: C, 62.46; H, 3.54; N, 20.34. ESI-HRMS (m/z)
20
21 calculated for $[M+H]^+$ 348.1091, found 348.1090.

22
23
24
25
26 **8-Amino-6-(3,4,5-trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3 (2H)-one (4).**

27
28 Yield 95%; mp 231-232 °C. Purified by column chromatography (eluent CHCl₃ 9.5/MeOH 0.5). ^1H
29
30 NMR (DMSO- d_6) 8.08 (d, 2H, ar, J = 7.7 Hz), 7.90 (s, 1H, H-5), 7.56-7.58 (m, 4H, 2ar + NH₂),
31
32 7.35 (t, 1H, ar, J = 7.4 Hz), 7.28 (s, 2H, ar), 3.87 (s, 6H, CH₃), 3.70 (s, 3H, CH₃). ^{13}C -NMR
33
34 (DMSO- d_6) 153.42, 147.67, 147.59, 138.07, 137.97, 135.74, 132.53, 131.56, 129.66, 126.76,
35
36 119.89, 103.48, 102.11, 60.53, 56.46. Anal. Calcd for C₂₀H₁₉N₅O₄: C, 61.06; H, 4.87; N, 17.80.
37
38 Found: C, 61.24; H, 4.62; N, 17.98. ESI-HRMS (m/z) calculated for $[M+H]^+$ 394.1510, found
39
40 394.1512.

41
42
43
44
45 **8-Amino-6-(4-methoxy-3,5-dimethylphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one**

46
47 **(5).** Yield 70%; mp 228-229 °C (EtOH). ^1H NMR (DMSO- d_6) 8.07 (d, 2H, ar, J = 7.8 Hz), 7.71-
48
49 7.66 (m, 3H, ar), 7.58-7.54 (m, 4H, ar + NH₂), 7.35 (t, 1H, ar, J = 7.4 Hz), 3.68 (s, 3H, CH₃), 2.27
50
51 (s, 6H, CH₃). ^{13}C -NMR (DMSO- d_6) 157.12, 147.75, 147.62, 137.96, 135.79, 132.02, 131.51,
52
53 130.67, 129.66, 126.76, 126.38, 119.91, 101.15, 59.79, 16.43. IR 3400, 3298, 1699. Anal. Calcd for
54
55 C₂₀H₁₉N₅O₂: C, 66.47; H, 5.30; N, 19.36. Found: C, 66.34; H, 5.63; N, 19.58. ESI-HRMS (m/z)
56
57 calculated for $[M+H]^+$ 362.1612, found 362.1609.
58
59
60

1
2
3
4
5 **8-Amino-6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-**
6 **one (6).** Yield 75%; mp 263-264 °C (2-methoxyethanol). ¹H NMR (DMSO-*d*₆) 8.08 (d, 2H, ar, J =
7 7.7 Hz), 7.78 (s, 2H, ar), 7.68 (s, 1H, ar), 7.56 (t, 2H, ar, J = 7.7 Hz), 7.54 (br. s, 2H, NH₂), 7.35 (t,
8 1H, ar, J = 7.4 Hz), 3.66 (s, 3H, CH₃), 1.44 (s, 18H, 2(CH₃)₃). ¹³C-NMR (DMSO-*d*₆) 159.69,
9 147.65, 143.48, 137.98, 136.56, 131.63, 131.53, 131.21, 131.17, 129.67, 126.77, 124.44, 119.88,
10 64.63, 36.01, 32.42. IR 3474, 3296, 1717. Anal. Calcd for C₂₆H₃₁N₅O₂: C, 70.09; H, 7.01; N, 17.72.
11 Found: C, 69.34; H, 7.16; N, 17.56. ESI-HRMS (m/z) calculated for [M+H]⁺ 446.2551, found
12 446.2551.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **General procedure for the Synthesis of Hydroxy-substituted 8-Amino-2-phenyl-1,2,4-**
28 **triazolo[4,3-*a*]pyrazin-3(2H)-ones (7-10).** 1 M solution of BBr₃ in CH₂Cl₂ (6 mL) was slowly
29 added at 0 °C, under nitrogen atmosphere, to a suspension of the methoxy-substituted
30 triazolopyrazines **1-2**, **4-5** (1 mmol) in anhydrous CH₂Cl₂ (20 mL). The mixture was stirred at rt for
31 a different time, depending on the compound structure, then was diluted with water (10 mL) and
32 neutralized with a NaHCO₃ saturated solution. Most of the organic solvent was removed by
33 evaporation at reduced pressure and the obtained solid was collected by filtration. The crude
34 derivatives were dried and purified by recrystallization (**8**) or by column chromatography (**7**, **9**, **10**).
35 The 4-hydroxy-2-methoxy- structure of **7** was determined by means of NOESY experiments
36 showing a spatial proximity between the OMe hydrogen atoms and the sole aromatic proton giving
37 a singlet at 6.53 ppm.
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **8-Amino-6-(4-hydroxy-2-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one (7).**
53 Reaction time 36 h. Yield 90%; mp 282-284 °C. Purified by column chromatography (eluent
54 cyclohexane 5/EtOAc 5/MeOH 1). ¹H NMR (DMSO-*d*₆) 9.67 (br s, 1H, OH), 8.07 (d, 2H, ar, J =
55 7.8 Hz), 7.91 (d, 1H, ar, J = 8.6 Hz), 7.77 (s, 1H, H-5), 7.56 (t, 2H, ar, J = 7.7 Hz), 7.39-7.33 (m,
56
57
58
59
60

3H, 1ar + NH₂), 6.53 (s, 1H, ar), 6.47 (d, 1H, ar, J = 8.5 Hz), 3.87 (s, 3H, CH₃). Anal. Calcd for C₁₈H₁₅N₅O₃: C, 61.89; H, 4.33; N, 20.05. Found: C, 61.75; H, 4.62; N, 20.17. ESI-HRMS (m/z) calculated for [M+H]⁺ 350.1248, found 350.1246.

8-Amino-6-(3,4-dihydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one (8).

Reaction time 4 h. Yield 90%; mp 256-258 °C (EtOH). ¹H NMR (DMSO-*d*₆) 9.08 (br s, 1H, OH), 8.98 (br s, 1H, OH), 8.08 (d, 2H, ar, J = 8.0 Hz), 7.55 (t, 2H, ar, J = 7.8 Hz), 7.49 (br s, 2H, NH₂) 7.44 (s, 1H, ar), 7.35 (s, 1H, ar), 7.35 (t, 1H, ar, J = 7.2 Hz), 7.23 (d, 1H, ar, J = 8.2 Hz), 6.77 (d, 1H, ar, J = 8.2 Hz). ¹³C-NMR (DMSO-*d*₆) 147.59, 147.56, 146.14, 145.66, 137.99, 136.46, 131.51, 129.65, 128.23, 126.71, 119.81, 117.26, 116.06, 113.69, 99.83. IR 3418-3092, 1693, 1682. Anal. Calcd for C₁₇H₁₃N₅O₃: C, 60.89; H, 3.91; N, 20.89. Found: C, 60.72; H, 4.15; N, 20.69. ESI-HRMS (m/z) calculated for [M+H]⁺ 336.1091, found 336.1092.

8-Amino-6-(3,4,5-trihydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one (9).

Reaction time 20 h. Yield 79%; mp 281-283 °C. Purified by column chromatography (eluent CHCl₃ 9/ MeOH 1). ¹H NMR (DMSO-*d*₆) 8.91 (br s, 2H, OH), 8.29 (br s, 1H, OH), 8.07 (d, 2H, ar, J = 7.8 Hz), 7.56 (t, 2H, ar, J = 7.6 Hz), 7.46 (br s, 2H, NH₂), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.30 (s, 1H, H-5), 6.85 (s, 2H, ar). Anal. Calcd for C₁₇H₁₃N₅O₄: C, 58.12; H, 3.73; N, 19.93. Found: C, 58.34; H, 3.55; N, 20.13. ESI-HRMS (m/z) calculated for [M+H]⁺ 352.1040, found 352.1039.

8-Amino-6-(4-hydroxy-3,5-dimethylphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazin-3(2H)-one

(10). Reaction time 4 h. Yield 90%; mp 236-237 °C. Purified by column chromatography (cyclohexane 1/EtOAc 1). ¹H NMR (DMSO-*d*₆) 8.40 (br s, 1H, OH), 8.07 (d, 2H, ar, J = 7.9 Hz), 7.50 (br s, 2H, NH₂), 7.55-7.68 (m, 6H, 5ar + H-5), 2.21 (s, 6H, 2CH₃). ¹³C-NMR (DMSO-*d*₆) 153.94, 147.64, 147.59, 137.99, 136.39, 131.49, 129.65, 127.54, 126.71, 126.04, 124.54, 119.85, 99.91, 17.21. IR 3550-3450, 3364, 3323, 1699. Anal. Calcd for C₁₉H₁₇N₅O₂: C, 65.69; H, 4.93; N,

20.16. Found: C, 65.84; H, 4.68; N, 20.02. ESI-HRMS (m/z) calculated for [M+H]⁺ 348.1455, found 348.1457.

8-Amino-6-(3-tert-butyl-4-hydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one

(11). Aqueous 48% HBr (2.50 mL) was added to a mixture of 8-amino-6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one **6** (0.5 mmol) in glacial acetic acid (2 mL). The mixture was refluxed for 24 h, then was treated with ice and water (30 mL). The obtained solid was collected by filtration, rinsed with Et₂O and petroleum ether, and purified by column chromatography (eluent CHCl₃ 9.5/MeOH 0.5). Yield 89%; mp > 300 °C; ¹H NMR (DMSO-d₆) 9.54 (s, 1H, OH), 8.08 (d, 2H, ar, J = 7.7 Hz), 7.72 (d, 1H, ar, J = 2.0 Hz), 7.58-7.54 (m, 3H, 2ar + H-5), 7.50 (s, 3H, ar + NH₂), 7.35 (t, 1H, ar, J = 7.4 Hz), 6.82 (d, 1H, ar, J = 8.3 Hz), 1.40 (s, 9H, (CH₃)₃). ¹³C NMR (DMSO-d₆) 170.84, 147.79, 147.61, 145.36, 144.95, 142.94, 139.58, 137.97, 135.74, 131.56, 131.45, 129.65, 128.73, 126.74, 126.33, 126.02, 119.85, 119.35, 101.01, 52.50, 45.14, 37.26. IR 3471.87, 3444.87, 1700.10, 1633.71, 1541.12, 1456.26. Anal. Calcd for C₂₁H₂₁N₅O₂: C, 67.18; H, 5.64; N, 18.65. Found: C, 67.34; H, 5.89; N, 18.40. Anal. Calcd for C₂₁H₂₁N₅O₂. ESI-HRMS (m/z) calculated for [M+H]⁺ 376.1768, found 376.1765.

2-(4-(8-Amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6

yl)phenoxy)acetonitrile (12). 2-Chloroacetonitrile (6.3 mmol) was added to a suspension of 6-(4-hydroxyphenyl)-triazolopyrazine derivative **49**²⁷ (1.6 mmol) and K₂CO₃ (3.1 mmol) in anhydrous acetone (20 mL). The mixture was stirred at rt for 16 h. The resulting solid was collected by filtration, washed with water (20 mL) and petroleum ether (20 mL), and purified by recrystallization. Yield 89%; mp 249-250 °C (EtOH). ¹H NMR (DMSO-d₆) 8.08 (d, 2H, ar, J = 7.7

1
2
3
4
5 Hz), 8.00 (d, 2H, ar, J = 8.8 Hz), 7.75 (s, 1H, H-5), 7.63–7.50 (m, 4H, 2ar + NH₂), 7.36 (t, 1H, ar, J
6 = 7.4 Hz), 7.13 (d, 2H, ar, J = 8.9 Hz), 5.22 (s, 2H). ¹³C NMR (DMSO-d₆) 156.74, 147.83, 147.63,
7 137.97, 135.42, 131.54, 131.23, 129.64, 127.46, 126.74, 119.87, 117.11, 115.28, 101.21, 54.01,
8 40.65, 40.44, 40.23, 40.02, 39.81, 39.60, 39.39. Anal. Calcd for C₁₉H₁₄N₆O₂: C, 63.68; H, 3.94; N,
9 23.45. Found: C, 63.96; H, 3.72; N, 23.68. ESI-HRMS (m/z) calculated for [M+H]⁺ 359.1251,
10 found 359.1252.
11
12
13
14
15
16
17
18
19
20
21

22 **2-(4-(8-Amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-**

23 **yl)phenoxy)acetamide (13).** The title compound was obtained by reacting the 6-(4-
24 hydroxyphenyl)-derivative **49**²⁷ (1.6 mmol) with 2-chloroacetamide (7.1 mmol) in the same
25 experimental condition employed to obtain **12** from **49**. Yield 51%; mp 260-263 °C (EtOH/ 2-
26 methoxyethanol). ¹H NMR (DMSO-d₆) 8.08 (d, 2H, ar, J = 7.8 Hz), 7.92 (d, 2H, ar, J = 8.3 Hz),
27 7.68 (s, 1H, H-5), 7.56-7.55 (m, 4H, 2ar + NH₂), 7.41 (br s, 2H, NH₂), 7.34 (t, 1H, ar, J = 7.2 Hz),
28 7.01 (d, 2H, ar, J = 8.3 Hz), 4.47 (s, 2H, CH₂). ¹³C NMR (DMSO-d₆) 170.32, 158.26, 147.78,
29 147.62, 137.98, 135.75, 131.53, 129.88, 129.64, 127.22, 126.74, 119.87, 115.12, 102.92, 100.73,
30 67.25, 43.05, 40.64, 40.43, 40.22, 40.01, 39.80, 39.59, 39.39. Anal. Calcd for C₁₉H₁₆N₆O₃: C,
31 60.63; H, 4.28; N, 22.33. Found: C, 60.48; H, 4.41; N, 22.04. ESI-HRMS (m/z) calculated for
32 [M+H]⁺ 377.1357, found 377.1358.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **8-Amino-6-(4-(2-aminoethoxy)phenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (14).**

51 The triazolopyrazine **12** (0.78 mmol) was added portion wise to a suspension of LiAlH₄ (1.95
52 mmol) in anhydrous THF (20 mL) at 0 °C. The mixture was stirred at rt for 2 h, then it was treated
53 with ice and water (15 mL) and extracted with EtOAc (20 mL x 3). The organic phase was washed
54 with water (20 mL x 3) and anhydridified (Na₂SO₄). The solvent was eliminated at reduced pressure
55
56
57
58
59
60

1
2
3
4
5 and the resulting solid was collected by filtration, dried and purified by column chromatography
6
7 (eluent CHCl₃ 9.5/ MeOH 0.5). Yield 78%; mp 239-241 °C. ¹H NMR (DMSO-d₆) 8.07 (d, 2H, ar, J
8 = 7.9 Hz), 7.90 (d, 2H, ar, J = 8.5 Hz), 7.65 (s, 1H, H-5), 7.60 – 7.45 (m, 4H, ar + NH₂), 7.35 (t,
9 1H, ar, J = 7.3 Hz), 6.98 (d, 2H, ar, J = 8.5 Hz), 3.96 (t, 2H, CH₂, J = 5.4 Hz), 2.89 (t, 2H, CH₂, J =
10 5.3 Hz). ¹³C-NMR (DMSO-d₆) 159.22, 147.76, 147.62, 137.99, 135.88, 131.53, 129.66, 129.20,
11 127.29, 126.75, 119.87, 114.87, 100.52, 70.66, 41.42. IR 3391, 3329, 3215, 1705, 1655. Anal.
12 Calcd for C₁₉H₁₈N₆O₂: C, 62.97; H, 5.01; N, 23.19. Found: C, 62.74; H, 4.85; N, 23.02. ESI-HRMS
13 (m/z) calculated for [M+H]⁺ 363.1564, found 363.1564.
14
15
16
17
18
19
20
21
22
23

24 **N-(2-(4-(8-Amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-6-**

25 **yl)phenoxy)ethyl)-5-(1,2-dithiolan-3-yl)pentanamide (15).** A mixture of the 6-(4-(2-
26 aminoethoxy)phenyl)-derivative **14** (0.66 mmol), (R,S) lipoic acid (0.73 mmol), 1-(3-
27 (dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride (0.76 mmol), triethylamine (1.12
28 mmol) and 1-hydroxybenzotriazole (0.76 mmol), in anhydrous DMF (1.5 mL), was stirred for about
29 2 h at rt. The mixture was diluted with water (20 mL) and the obtained solid was collected by
30 filtration, rinsed with water (3 mL), Et₂O (10 mL), dried and purified by column chromatography
31 (eluent cyclohexane 2/EtOAc 8) and then recrystallized. Yield 82%; mp 202-204 °C
32 (nitromethane). ¹H NMR (DMSO-d₆) 8.09-8.06 (m, 3H, 2ar + NH), 7.91 (d, 2H, ar, J = 8.1 Hz),
33 7.66 (s, 1H, H-5), 7.63–7.49 (m, 4H, 2ar + NH₂), 7.36 (t, 1H, ar, J = 7.3 Hz), 6.99 (d, 2H, ar, J = 8.2
34 Hz), 4.02 (d, 2H, CH₂-O, J = 5.0 Hz), 3.64–3.53 (m, 1H, CH), 3.46-3.43 (m, 2H, 2CH), 3.21–3.02
35 (m, 2H, 2CH), 2.38-2.30 (m, 1H, CH), 2.11-2.03 (m, 2H, CH₂), 1.90 – 1.75 (m, 1H, CH), 1.65-1.60
36 (m, 1H, CH), 1.56-1.48 (m, 3H, CH₂ + CH), 1.35-1.31 (m, 2H, CH₂). ¹³C NMR (DMSO-d₆) 172.80,
37 158.97, 147.77, 147.62, 137.99, 135.82, 131.53, 129.66, 129.40, 127.30, 126.75, 119.87, 114.90,
38 66.89, 56.59, 38.68, 38.55, 35.56, 34.57, 28.72, 25.47. IR 3358, 3285, 1709, 1628. Anal. Calcd for
39 C₂₇H₃₀N₆O₃S₂: C, 58.89; H, 5.49; N, 15.26. Found: C, 58.65; H, 5.78; N, 15.04. ESI-HRMS (m/z)
40 calculated for [M+H]⁺ 551.1894, found 551.1897.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

N-(2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-6-

yl)phenoxy)ethyl)-3,5-di-*tert*-butyl-4-hydroxybenzamide (16). The title compound was synthesized by reacting the 6-(4-(2-aminoethoxy)phenyl) derivative **14** (0.66 mmol) and 3,5-di-*tert*-butyl-4-hydroxybenzoic acid (0.73 mmol) in the same experimental conditions described above to prepare compound **17** from **16**. The crude compound was purified by column chromatography (eluent cyclohexane 4/ EtOAc 6). Yield 78%; mp 259-260 °C. ¹H NMR (DMSO-*d*₆) 8.51 (t, 1H, NH, *J* = 5.5 Hz), 8.08 (d, 2H, ar, *J* = 7.9 Hz), 7.91 (d, 2H, ar, *J* = 8.7 Hz), 7.66 (s, 1H, H-5), 7.63 (s, 2H, ar), 7.59–7.54 (m, 4H, 2ar + NH₂), 7.39 (s, 1H, OH), 7.36 (t, 1H, ar, *J* = 7.4 Hz), 7.02 (d, 2H, ar, *J* = 8.8 Hz), 4.15 (t, 2H, CH₂, *J* = 5.8 Hz), 3.62 (d, 2H, CH₂, *J* = 5.6 Hz), 1.41 (s, 18H, 2(CH₃)₃). ¹³C NMR (DMSO-*d*₆) 167.75, 158.99, 157.14, 147.77, 147.61, 144.69, 138.69, 137.98, 137.34, 135.84, 131.53, 129.64, 129.39, 127.33, 126.75, 125.97, 124.54, 119.87, 114.90, 66.69, 35.05, 30.68. IR 3315, 3213, 1699, 1616, 1456 1377, 1315, 1248, 1178. Anal. Calcd for C₃₄H₃₈N₆O₄: C, 68.67; H, 6.44; N, 14.13. Found: C, 68.88; H, 6.67; N, 14.35. ESI-HRMS (*m/z*) calculated for [M+H]⁺ 595.3027, found 595.3028.

N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-6-yl)phenyl)-5-(1,2-

dithiolan-3-yl)pentanamide (17). The title compound was obtained by reacting the 6-(4-aminophenyl) derivative **50**³³ (1.00 mmol) with (R,S) lipoic acid (1.35 mmol) in the same experimental conditions described above to synthesize **15** from **14**. The crude compound was purified by recrystallization. Yield 95%; mp 229-233 °C (nitromethane). ¹H-NMR (DMSO-*d*₆) 9.96 (br s, 1H, NH), 8.08 (d, 2H, ar, *J* = 7.9 Hz), 7.91 (d, 2H, ar, *J* = 8.7 Hz), 7.69 (s, 1H, H-5), 7.65 (d, 2H, ar, *J* = 8.7 Hz), 7.58-7.64 (m, 4H, ar + NH₂), 7.35 (t, 1H, ar, *J* = 7.4 Hz), 3.64-3.66 (m, 1H, CH), 3.19-3.14 (m, 2H, 2CH), 2.43-2.44 (m, 1H, CH), 2.28-2.32 (m, 2H, CH₂), 1.88-1.85 (m, 1H, CH), 1.73-1.55 (m, 4H, 2CH₂), 1.43-1.36 (m, 2H, CH₂). ¹³C-NMR (DMSO-*d*₆) 171.60; 147.79;

1
2
3
4
5 147.61; 139.68; 137.98; 135.75; 131.56; 131.39; 129.67; 126.75; 126.31; 120.00; 119.30; 100.98;
6
7 56.58; 38.58; 36.74; 34.64; 28.82; 25.35. IR 3431, 3312, 3208, 1694, 1682. Anal. Calcd for
8
9 $C_{25}H_{26}N_6O_2S_2$: C, 59.27; H, 5.17; N, 16.59. Found: C, 59.04; H, 5.36; N, 16.42. ESI-HRMS (m/z)
10
11 calculated for $[M+H]^+$ 507.1631, found 507.1628.
12
13
14
15
16
17

18 **N-(4-(8-Amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-**

19 **yl)phenyl)acrylamide (18).** A mixture of the 6-(4-aminophenyl)-derivative **50**³³ (1.0 mmol), 3-
20
21 chloropropionic acid (1.2 mmol), 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide
22
23 hydrochloride (0.76 mmol) and triethylamine (1.12 mmol), in anhydrous DMF (1.5 mL) was stirred
24
25 for about 2h at rt. The suspension was diluted with water (20 mL) and the obtained solid was
26
27 collected by filtration, rinsed with water (3 mL), Et₂O (10 mL), dried and purified by
28
29 recrystallization. Yield 92%; mp > 300 °C (nitromethane). ¹H-NMR (DMSO-d₆) 10.33 (br s, 1H,
30
31 NH), 8.07 (d, 2H, ar, J = 7.9 Hz), 7.93 (d, 2H, ar, J = 8.9 Hz), 7.75 (d, 2H, ar, J = 8.5 Hz), 7.69 (s,
32
33 1H, H-5), 7.54-7.52 (m, 4H, 2ar + NH₂) 7.33 (t, 1H, ar, J = 7.2 Hz), 6.47 (dd, 1H, CH, J = 16.9,
34
35 10.0 Hz), 6.28 (d, 1H, CH, J = 16.9 Hz), 5.77 (d, 1H, CH, J = 10.0 Hz). ¹³C-NMR (DMSO-d₆)
36
37 163.63, 147.79, 147.59, 139.40, 137.96, 135.70, 132.36, 131.91, 131.54, 129.60, 127.28, 126.69,
38
39 126.37, 119.82, 119.65, 101.15. IR 3376, 3331, 3296, 3206, 3181, 1694, 1681.93, 1643, 1634.
40
41 Anal. Calcd for $C_{20}H_{16}N_6O_2$: C, 64.51; H, 4.33; N, 22.57. Found: C, 64.42; H, 4.54; N, 22.72. ESI-
42
43 HRMS (m/z) calculated for $[M+H]^+$ 373.1408, found 373.1403.
44
45
46
47
48
49
50
51
52

53 **3-Amino-N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-**

54 **yl)phenyl)propanamide (19).** A suspension of the acrylamido derivative **18** (0.13 mmol) in ethanol
55
56 saturated solution with NH₃ (15 mL) was heated at 130 °C in a sealed tube for 3 h. The mixture was
57
58 cooled at rt and the solid was collected by filtration, washed with water (about 5-10 mL), dried and
59
60

1
2
3
4
5 purified by column chromatography (eluent CH₂Cl₂ 8/MeOH 2/ 33% NH₃ aqueous solution 0.2).
6
7 Yield 89%; mp 239-241 °C. ¹H-NMR (DMSO-d₆) 10.18 (br s, 1H, NH), 8.08 (d, 2H, ar, J = 7.9
8 Hz), 7.91 (d, 2H, ar, J = 8.7 Hz), 7.69 – 7.65 (m, 3H, 2ar + H-5), 7.58-7.54 (m, 4H, 2ar + NH₂, J =
9 7.8 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 2.87 (t, 2H, CH₂, J = 6.2 Hz), 2.43 (t, 2H, CH₂, J = 6.4 Hz).
10
11 ¹³C-NMR (DMSO-d₆) 170.98, 147.79, 147.61, 139.63, 137.98, 135.76, 131.56, 131.40, 129.65,
12 126.74, 126.31, 119.85, 119.33, 100.98, 39.37, 38.45. Anal. Calcd for C₂₀H₁₉N₇O₂: C, 61.69; H,
13 4.92; N, 25.18. Found: C, 61.45; H, 4.85; N, 25.36. ESI-HRMS (m/z) calculated for [M+H]⁺
14 390.1673, found 390.1673.
15
16
17
18
19
20
21
22
23

24 **N-(3-((4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-**

25 **yl)phenyl)amino)-3-oxopropyl)-5-(1,2-dithiolan-3-yl)pentanamide (20).** The title compound **20**
26 was synthesized by reacting compound **19** (1.0 mmol) and (R,S) lipoic acid (1.1 mmol) in the same
27 experimental conditions described above to prepare compound **15** from **14**. The crude derivative
28 was purified by column chromatography (CH₂Cl₂ 9.7/MeOH 0.3) and then recrystallized. Yield
29 65%; mp 250-251 °C (nitromethane). ¹H NMR (DMSO-d₆) 10.03 (br s, 1H, NH), 8.08 (d, 2H, ar, J
30 = 7.9 Hz), 7.92 (m, 3H, 2ar + NH), 7.69 – 7.65 (m, 3H, 2ar + H-5), 7.58 – 7.54 (m, 4H, 2ar + NH₂),
31 7.35 (t, 1H, ar, J = 7.4 Hz), 3.59 – 3.52 (m, 1H, CH), 3.45-3.41 (m, 2H, CH₂), 3.19 – 3.12 (m, 1H,
32 CH), 3.11-3.04 (m, 1H, CH), 2.58-2.54 (m, 2H, CH₂), 2.31-2.36 (m, 1H, CH), 2.07 (t, 2H, J = 7.2
33 Hz), 1.89-1.83 (m, 1H, CH), 1.66-1.59 (m, 1H), 1.54-1.47 (m, 3H), 1.36 – 1.29 (m, 2H). ¹³C-NMR
34 (DMSO-d₆) 172.57, 170.00, 147.79, 147.62, 139.59, 137.98, 135.75, 131.56, 131.49, 129.66,
35 126.76, 126.30, 119.87, 119.36, 101.01, 56.57, 38.54, 36.97, 35.60, 35.50, 34.59, 28.71, 25.56.
36 Anal. Calcd for C₂₈H₃₁N₇O₂S₂: C, 58.21; H, 5.41; N, 16.97. Found: C, 57.96; H, 5.53; N, 16.68.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ESI-HRMS (m/z) calculated for [M+H]⁺ 578.2003, found 578.2007.

N-(3-((4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-yl)phenyl)amino)-3-oxopropyl)-3,5-di-tert-butyl-4-hydroxybenzamide (21). The title compound was synthesized by reacting compound **20** (1.0 mmol) and 3,5-di-tert-butyl-4-hydroxybenzoic acid (0.73 mmol) in the same experimental conditions described above to prepare compound **15** from **14**. Yield 90%; mp > 300 °C (nitromethane). ¹H NMR (DMSO-d₆) 10.05 (s, 1H, NH), 8.42 (t, 1H, J = 5.5 Hz), 8.08 (d, 2H, ar, J = 7.9 Hz), 7.91 (d, 2H, ar, J = 8.6 Hz), 7.69 – 7.65 (m, 3H, 2ar, + H-5), 7.60-7.54 (m, 6H, 4ar + NH₂), 7.42 – 7.30 (m, 2H, 1ar + OH), 3.53 (dd, 2H, CH₂, J = 12.4, 6.4 Hz), 2.63 (t, 2H, CH₂, J = 6.8 Hz), 1.39 (s, 18H, 2(CH₃)₃). ¹³C NMR (DMSO-d₆) 170.19, 167.64, 157.02, 147.80, 147.62, 139.58, 138.66, 137.99, 135.77, 131.57, 131.52, 129.64, 126.75, 126.29, 124.47, 119.88, 119.45, 101.02, 37.19, 36.38, 35.03, 30.68. Anal. Calcd for C₃₅H₃₉N₇O₄: C, 67.61; H, 6.32; N, 15.77. Found: C, 67.75; H, 6.58; N, 15.89. ESI-HRMS (m/z) calculated for [M+H]⁺ 622.3136, found 622.3127

General Procedure for the Synthesis of 2-Bromo-1-arylethanones 27 and 28. A solution of bromine (5.66 mmol) in CHCl₃ (5 ml) was added dropwise to a solution of the commercial 1-(3,5-dimethyl-4-methoxyphenyl)ethanone **29** (5.7 mmol) or suitably prepared 1-(3,5-ditert-butyl-4-methoxyphenyl)ethanone **30** (5.7 mmol) in Et₂O (10 ml) and CHCl₃ (5 ml), maintaining the temperature at 0 °C. After the addition was completed, the mixture was stirred at rt for 2 h, then it was diluted with CHCl₃ (about 5 ml). The solution was washed with brine (20 mL) and water (20 mL x 3). The anhydrous (Na₂SO₄) organic phase was evaporated at reduced pressure to give an oily residue which was used directly in the next step.

2-Bromo-1-(3,5-dimethyl-4-methoxyphenyl)ethanone (27). Yield 75%. ¹H NMR (CDCl₃) 7.69 (s, 2H, ar), 4.43 (s, 2H, CH₂), 3.80 (s, 3H, CH₃), 2.36 (s, 6H, 2CH₃).

1
2
3
4
5 **2-Bromo-1-(3,5-di-tert-butyl-4-methoxyphenyl)ethanone (28)**. Yield 96%. ¹H NMR (CDCl₃)

6
7
8 7.94 (s, 2H, ar), 4.43 (s, 2H, CH₂), 3.75 (s, 3H, CH₃), 1.47 (s, 18H, 2(CH₃)₃).
9

10
11
12
13 **1-(3,5-Di-tert-butyl-4-methoxyphenyl)ethanone (30)**

14
15 A suspension of 1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone⁴⁹ (9.3 mmol), CH₃I (46.3 mmol)
16 and potassium carbonate (13.9 mmol) in 2-butanone (25 mL) was refluxed for about 72 h under
17 nitrogen atmosphere. During this time, other five portions of CH₃I (each of 46.3 mmol) were added.
18 After the reaction was completed, the obtained solid was filtered off and the mother solution was
19 evaporated at reduced pressure. The residue was taken up with Et₂O (20 mL) and the solid obtained
20 was filtered off. The solvent was evaporated at reduced pressure to give an orange semisolid residue
21 which was pure enough (TLC, NMR) to be used for the next step without further purification. Yield
22 95%. ¹H NMR (CDCl₃) 7.90 (s, 2H, ar), 3.74 (s, 3H, CH₃), 2.59 (s, 3H, CH₃), 1.47 (s, 18H,
23 2(CH₃)₃).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **General Procedure for the Synthesis of Ethyl 1-phenyl-5-oxo-4-(2-aryl-2-oxoethyl)-4,5-**
40 **dihydro-1H-1,2,4-triazole-3-carboxylates 31-36**. The suitable α -bromoketone **23-26**⁴⁵⁻⁴⁸ or **27** and
41 **28** (1.2 mmol) was added to a mixture of ethyl 1-phenyl-5-oxo-1,2,4-triazole-3-carboxylate **22**⁴⁴ (1
42 mmol) and potassium carbonate (2 mmol) in DMF/CH₃CN (1:9, 10 mL). The suspension was
43 stirred at rt until the disappearance of the starting material (TLC monitoring, 2-24 h). The solvent
44 was removed at reduced pressure and the residue was treated with water (50-70 mL). The resulting
45 precipitate was collected by filtration, washed with water (30 mL), Et₂O (20 mL) and then
46 recrystallized. Compound **31** was purified by column chromatography.
47
48
49
50
51
52
53
54
55
56

57 **Ethyl 4-[2-(2,4-dimethoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-**
58 **carboxylate (31)**. Yield 85%; mp 150-152 °C. Purified by column chromatography (eluent
59
60

1
2
3
4
5 cyclohexane 6/ EtOAc 4). ¹H NMR (CDCl₃) 7.99-8.07 (m, 3H, ar), 7.47 (t, 2H, ar, J = 7.8 Hz), 7.30
6 (t, 1H, ar, J = 7.3 Hz), 6.61 (dd, 1H, ar, J = 1.9 Hz, J = 6.8 Hz) 6.53 (d, 1H, ar, J = 1.8 Hz), 5.45 (s,
7 2H, CH₂), 4.41 (q, 2H, CH₂, J = 7.1 Hz), 3.98 (s, 3H, CH₃), 3.96 (s, 3H, CH₃), 1.38 (t, 3H, CH₃, J =
8 7.1 Hz). Anal. Calcd for C₂₁H₂₁N₃O₆: C, 61.31; H, 5.14; N, 10.21. Found: C, 61.20; H, 5.29; N,
9 10.34.
10
11
12
13
14
15

16
17 **Ethyl 4-(2-(3,4-dimethoxyphenyl)-2-oxoethyl)-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-**
18 **carboxylate (32)**. Yield 80%; mp 159-161 °C (EtOH). ¹H-NMR (CDCl₃) 8.04 (d, 2H, ar, J = 7.92
19 Hz), 7.69 (d, 1H, ar, J = 8.4 Hz), 7.55 (s, 1H, ar), 7.48 (t, 2H, ar, J = 7.6 Hz), 7.32 (t, 1H, ar, J = 7.4
20 Hz), 6.98 (d, 1H, ar, J = 8.4 Hz), 5.55 (s, 2H, CH₂), 4.41 (q, 2H, CH₂, J = 7.1 Hz), 4.01 (s, 3H,
21 CH₃), 3.97 (s, 3H, CH₃), 1.41 (t, 3H, CH₃, J = 7.1 Hz). Anal. Calcd for C₂₁H₂₁N₃O₆: C, 61.31; H,
22 5.14; N, 10.21. Found: C, 61.04; H, 5.36; N, 10.03.
23
24
25
26
27
28
29
30
31
32
33

34 **Ethyl 4-[2-(3,4-methylenedioxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-**
35 **triazole-3-carboxylate (33)**. Yield 77%; mp 179-181 °C (cyclohexane/EtOAc). ¹H NMR (CDCl₃)
36 8.03 (d, 2H, ar, J = 8.0 Hz), 7.65 (d, 1H, ar, J = 8.2 Hz), 7.48 (t, 3H, ar, J = 8.0 Hz), 7.31 (t, 1H, ar, J
37 = 7.6 Hz), 6.94 (d, 1H, ar, J = 8.2 Hz), 6.11 (s, 2H, CH₂), 5.50 (s, 2H, CH₂), 4.42 (q, 2H, CH₂, J =
38 7.1 Hz), 1.39 (t, 3H, CH₃, J = 7.1 Hz). Anal. Calcd for C₂₀H₁₇N₃O₆: C, 60.76; H, 4.33; N, 10.63.
39 Found: C, 60.58; H, 4.48; N, 10.58.
40
41
42
43
44
45
46
47
48
49
50

51 **Ethyl 4-[2-(3,4,5-trimethoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-**
52 **triazole-3-carboxylate (34)**. Yield 95%; mp 131-133 °C (cyclohexane/EtOAc). ¹H NMR (CDCl₃)
53 8.04 (d, 2H, ar, J = 8.6 Hz), 7.49 (t, 2H, ar, J = 7.4 Hz), 7.27-7.34 (m, 3H, ar), 5.55 (s, 2H, CH₂),
54
55
56
57
58
59
60

3.96 (br s, 9H, 3CH₃), 4.43 (q, 2H, CH₂, J = 7.1 Hz), 1.41 (t, 3H, CH₃, J = 7.1 Hz). Anal. Calcd for C₂₂H₂₃N₃O₇: C, 59.86; H, 5.25; N, 9.52. Found: C, 60.15; H, 5.04; N, 9.36.

Ethyl 4-(2-(4-methoxy-3,5-dimethylphenyl)-2-oxoethyl)-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (35). Yield 70%; mp 140-142 °C (EtOH). ¹H NMR (CDCl₃) 8.04 (d, 2H, ar, J = 8.1 Hz), 7.71 (s, 2H, ar), 7.48 (t, 2H, ar, J = 7.9 Hz), 7.31 (t, 1H, ar, J = 7.2 Hz), 5.52 (s, 2H, CH₂), 4.41 (q, 2H, CH₂, J = 7.1 Hz), 3.81 (s, 3H, CH₃), 2.38 (s, 6H, CH₃), 1.39 (t, 3H, CH₃, J = 7.1 Hz). Anal. Calcd for C₂₂H₂₃N₃O₅: C, 64.54; H, 5.66; N, 10.26. Found: C, 64.36; H, 5.85; N, 10.08.

Ethyl 4-(2-(3,5-di-tert-butyl-4-methoxyphenyl)-2-oxoethyl)-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (36). Yield 60%; mp 196-198 °C (EtOH). ¹H NMR (CDCl₃) 8.04 (d, 2H, ar, J = 7.8 Hz), 7.94 (s, 2H, ar), 7.48 (t, 2H, ar, J = 7.7 Hz), 7.32 (t, 1H, ar, J = 7.5 Hz), 5.56 (s, 2H, CH₂), 4.42 (q, 2H, CH₂, J = 7.1 Hz), 3.76 (s, 3H, CH₃), 1.48 (s, 18H, (CH₃)₃), 1.40 (t, 3H, CH₃, J = 7.1 Hz). Anal. Calcd for C₂₈H₃₅N₃O₅: C, 68.13; H, 7.15; N, 8.51. Found: C, 68.36; H, 6.92; N, 8.74.

General Procedure for the Synthesis of 1,2,4-Triazolo[4,3-*a*]pyrazine-3,8(2*H*,7*H*)-dione derivatives 37-42. A mixture of the suitable ethyl 1,2,4-triazole-3-carboxylate derivatives **31-36** (0.9 mmol) and anhydrous ammonium acetate (3.5 mmol) was heated in a sealed tube at 140 °C until the disappearance of starting material (TLC monitoring, 3-24 h). The residue was taken up with EtOH (1 mL) and Et₂O (5 mL), collected by filtration and washed with water (20 mL). All the crude compounds were purified by recrystallization.

6-(2,4-Dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-*a*]pyrazine-3,8(2*H*,7*H*)-dione (37). Yield 64%; mp 252-254 °C (AcOH). ¹H NMR (DMSO-*d*₆) 11.34 (br s, 1H, NH), 8.00 (d, 2H, ar, J = 7.7

1
2
3
4
5 Hz), 7.55 (t, 2H, ar, J = 7.6 Hz), 7.33-7.37 (m, 2H, ar), 6.93 (s, 1H, H-5), 6.67 (d, 1H, ar, J = 2.3
6
7 Hz), 6.60 (dd, 1H, ar, J = 2.4, 6.1 Hz), 3.84 (s, 6H, 2CH₃). Anal. Calcd for C₁₉H₁₆N₄O₄: C, 62.63;
8
9 H, 4.43; N, 15.38. Found: C, 62.85; H, 4.25; N, 15.20.

11 **6-(3,4-Dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (38).** Yield
12 53%; mp > 300 °C (EtOH/2-methoxyethanol). ¹H NMR (DMSO-d₆) 11.54 (br s, 1H, NH), 8.02 (d,
13
14 2H, ar, J = 7.9 Hz), 7.56 (t, 2H, ar, J = 7.7 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.27-7.29 (m, 3H, 2 ar +
15
16 H-5), 7.03 (d, 1H, ar, J = 9.0 Hz), 3.87 (s, 3H, OCH₃), 3.81 (s, 3H, OCH₃). Anal. Calcd for
17
18 C₁₉H₁₆N₄O₄: C, 62.63; H, 4.43; N, 15.38. Found: C, 62.84; H, 4.36; N, 15.52.

21 **6-(3,4-Methylenedioxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (39).**
22
23 Yield 78%; mp 279-281 °C (AcOH/DMF). ¹H NMR (DMSO-d₆) 11.53 (br s, 1H, NH), 8.01 (d, 2H,
24
25 ar, J = 7.8 Hz) 7.56 (t, 2H, ar, J = 7.7 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.30 (d, 1H, ar, J = 1.6 Hz),
26
27 7.20-7.23 (m, 2H, 1 ar, H-5), 7.01 (d, 1H, ar, J = 8.2 Hz), 6.10 (s, 2H, CH₂). Anal. Calcd for
28
29 C₁₈H₁₂N₄O₄: C, 62.07; H, 3.47; N, 16.09. Found: C, 62.35; H, 3.25; N, 16.28.

32 **6-(3,4,5-Trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (40).**
33
34 Yield 25%; mp > 300 °C (AcOH/DMF). ¹H NMR (DMSO-d₆) 11.59 (br s, 1H, NH), 8.02 (d, 2H, ar,
35
36 J = 7.7 Hz) 7.57 (t, 2H, ar, J = 7.7 Hz), 7.49 (s, 1H, H-5), 7.37 (t, 1H, ar, J = 7.4 Hz), 7.02 (s, 2H,
37
38 ar), 3.89 (s, 6H, CH₃), 3.70 (s, 3H, CH₃). Anal. Calcd for C₂₀H₁₈N₄O₅: C, 60.91; H, 4.60; N, 14.21.
39
40 Found: C, 60.75; H, 4.45; N, 14.02.

43 **6-(4-Methoxy-3,5-dimethylphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione**
44
45 **(41).** Yield 70%; mp > 300 °C (2-methoxyethanol/DMF). ¹H NMR (DMSO-d₆) 11.48 (br s, 1H,
46
47 NH), 8.01 (d, 2H, ar, J = 7.9 Hz), 7.56 (t, 2H, ar, J = 7.9 Hz), 7.44 (s, 2H, ar), 7.36 (t, 1H, ar, J = 7.4
48
49 Hz), 7.21 (s, 1H, ar), 3.70 (s, 3H, CH₃), 2.28 (s, 6H, CH₃). Anal. Calcd for C₂₀H₁₈N₄O₃: C, 66.29;
50
51 H, 5.01; N, 15.46. Found: C, 66.05; H, 5.25; N, 15.35.

1
2
3
4
5 **6-(3,5-Di-tert-butyl-4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-**
6 **dione (42).** Yield 75%; mp > 300°C (AcOH/DMF). ¹H NMR (DMSO-d₆) 11.63 (br s, 1H, NH),
7 8.02 (d, 2H, ar, J = 8.2 Hz), 7.56 (t, 2H, ar, J = 7.4 Hz), 7.49 (s, 2H, ar), 7.36 (t, 1H, ar, J = 7.4 Hz),
8 7.24 (s, 1H, ar), 3.67 (s, 3H, CH₃), 1.44 (s, 18H, 2(CH₃)₃). Anal. Calcd for C₂₆H₃₀N₄O₃: C, 69.93;
9 H, 6.77; N, 12.55. Found: C, 70.24; H, 6.68; N, 12.37.
10
11
12
13
14
15
16
17

18 **General Procedure for the Synthesis of 6-Aryl-8-chloro-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-**
19 **3-(2H)-ones 43-48.** A suspension of the suitable 8-oxo-triazolopyrazine derivatives **37-42** (2.0
20 mmol) in phosphorus oxychloride (12 mL) was heated under microwave irradiation at 170 °C for 1h
21 and 30 min. The excess of phosphorus oxychloride was distilled off and the residue was treated
22 with ice and water (about 10-20 mL). The obtained solid was collected by filtration, washed
23 abundantly with water and dried. These intermediates were pure enough (NMR, TLC) to be used
24 for the next step without further purification.
25
26
27
28
29
30
31
32
33

34
35 **8-Chloro-6-(2,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (43).** Yield
36 96%; ¹H NMR (DMSO-d₆) 8.34 (s, 1H, H-5), 8.06 (d, 2H, ar, J = 7.8 Hz), 7.92 (d, 1H, ar, J = 8.6
37 Hz), 7.58 (t, 2H, ar, J = 7.6 Hz), 7.39 (t, 1H, ar, J = 7.4 Hz), 6.71-6.75 (m, 2H, ar), 3.97 (s, 3H,
38 CH₃), 3.90 (s, 3H, CH₃).
39
40
41
42
43

44 **8-Chloro-6-(3,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (44).** Yield
45 85%; ¹H NMR (DMSO-d₆) 8.63 (s, 1H, H-5), 8.08 (d, 2H, ar, J = 8.1 Hz), 7.62-7.58 (m, 4H, ar),
46 7.41 (t, 1H, ar, J = 7.4 Hz), 7.06 (d, 1H, ar, J 0 8.2 Hz), 3.88 (s, 3H, CH₃), 3.81 (s, 3H, CH₃).
47
48
49
50

51 **8-Chloro-6-(3,4-methylenedioxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (45).**
52 Yield 64%; ¹H NMR (DMSO-d₆) 8.55 (s, 1H, H-5), 8.07 (d, 2H, ar, J = 8.0 Hz), 7.65 (s, 1H, ar),
53 7.57-7.59 (m, 3H, ar), 7.40 (t, 1H, ar, J = 7.3 Hz), 7.03 (d, 1H, ar, J = 8.1 Hz), 6.10 (s, 2H, CH₂).
54
55
56
57
58
59
60

8-Chloro-6-(3,4,5-trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (46).

Yield 96%; ¹H NMR (DMSO-d₆) 8.79 (s, 1H, H-5), 8.07 (d, 2H, ar, J = 7.9 Hz), 7.62 (t, 2H, ar, J = 7.8 Hz), 7.33 (s, 2H, ar), 7.41 (t, 1H, ar, J = 7.6 Hz), 3.89 (s, 6H, 2CH₃), 3.71 (s, 3H, CH₃).

8-Chloro-6-(4-methoxy-3,5-dimethylphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one

(47). Yield 82%; ¹H NMR (DMSO-d₆) 8.48 (s, 1H, ar), 8.07 (d, 2H, ar, J = 8.1 Hz), 7.73 (s, 2H, ar), 7.59 (t, 2H, ar, J = 7.9 Hz), 7.41 (t, 1H, ar, J = 7.5 Hz), 3.70 (s, 3H, CH₃), 2.30 (s, 6H, CH₃).

8-Chloro-6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-

one (48). Yield 90%; ¹H NMR (DMSO-d₆) 8.65 (s, 1H, ar), 8.07 (d, 2H, ar, J = 7.9 Hz), 7.85 (s, 2H, ar), 7.60 (t, 2H, ar, J = 7.8 Hz), 7.41 (t, 1H, ar, J = 7.6 Hz), 3.67 (s, 3H, CH₃), 1.45 (s, 18H, 2(CH₃)₃).

Molecular Modeling. *Refinement of the hA_{2A} AR and hA₁ AR Structures.* The crystal structure of the hA_{2A} AR in complex with ZM241385 was retrieved from the Protein Data Bank (<http://www.rcsb.org>; pdb code: 5NM4; 1.7-Å resolution⁵²) and added of all hydrogen atoms within MOE (Molecular Operating Environment 2014.09).⁵⁰ The crystal structure of the hA₁ AR covalently bound to an antagonist was retrieved from the Protein Data Bank (pdb code: 5N2S; 3.3-Å resolution⁵³). The structure was prepared for docking studies following analogue protocol as described for the 5NM4 A_{2A} AR structure.

Molecular docking analysis. All compound structures were docked into the binding site of the AR structures using the Induced Fit docking protocol of MOE and the genetic algorithm docking tool of CCDC Gold.^{50,51} The Induced Fit docking protocol of MOE is divided into a number of stages: *Conformational Analysis of ligands.* The algorithm generated conformations from a single 3D conformation by conducting a systematic search. In this way, all combinations of angles were created for each ligand. *Placement.* A collection of poses was generated from the pool of ligand

1
2
3
4
5 conformations using Alpha Triangle placement method. Poses were generated by superposition of
6
7 ligand atom triplets and triplet points in the receptor binding site. The receptor site points are alpha
8
9 sphere centers which represent locations of tight packing. At each iteration, a random conformation
10
11 was selected, a random triplet of ligand atoms and a random triplet of alpha sphere centers were
12
13 used to determine the pose. *Scoring*. Poses generated by the placement methodology were scored
14
15 using the *Alpha HB* scoring function, which combines a term measuring the geometric fit of the
16
17 ligand to the binding site and a term measuring hydrogen bonding effects. *Induced Fit*. The
18
19 generated docking conformations were subjected to energy minimization within the binding site and
20
21 the protein sidechains are included in the refinement stage. In detail, the protein backbone is set as
22
23 rigid while the side chains are not set to “free to move” but are set to “tethered”, where an atom
24
25 tether is a distance restraint that restrains the distance not between two atoms but between an atom
26
27 and a fixed point in space. *Rescoring*. Complexes generated by the Induced Fit methodology stage
28
29 were scored using the *Alpha HB* scoring function. Gold tool was used with default efficiency
30
31 settings through MOE interface, by selecting ChemScore as scoring function.
32
33
34
35
36
37
38

39 **Stability Studies.** *Chemicals*. Acetonitrile (Chromasolv), formic acid (MS grade),
40
41 tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl), verapamil hydrochloride (analytical
42
43 standard, used as internal standard) and ketoprofen (analytical standard) were purchased by Sigma-
44
45 Aldrich (Milan, Italy). Ketoprofen Ethyl Ester (KEE) were obtained by Fisher's reaction from
46
47 ketoprofen and ethanol. MilliQ water 18 M Ω was obtained from Millipore's Simplicity system
48
49 (Milan-Italy). The 50 mM Tris buffer solution was prepared dissolving 0.8 g of
50
51 tris(hydroxymethyl)aminomethane hydrochloride in 0.1 L of MilliQ water. Human plasma was
52
53 collected from healthy volunteers, pooled and kept at -80 °C until use.
54
55
56

57 *Instrumental*. The LC-MS/MS analysis was carried out using a Varian 500 MS ion trap system
58
59 (Palo Alto, CA, USA) equipped by two Prostar 210 pumps, a Prostar 410 autosampler and an
60

1
2
3
4
5 Electrospray Source (ESI) operating in positive ions. Raw-data were collected and processed by
6
7 Varian Workstation vers. 6.9 software. G-Therm 015 thermostatic oven was used to maintain the
8
9 samples at 37 °C during the test of degradation. ALC micro centrifuge 4214 was employed to
10
11 centrifuge plasma samples.
12

13
14 The LC-MS/MS parameters, the preparation of the calibration solutions, the linearity of calibration
15
16 curve and the limit of detection of the quantitative method, for each studied compound, were
17
18 reported in Supporting Information.
19
20
21
22

23 **Pharmacology**

24
25
26 **Binding Assay.** *Membrane preparation.* Membranes for radioligand binding were prepared as
27
28 described earlier.²⁷ In brief, after homogenization of CHO (Chinese Hamster Ovary) cells stably
29
30 transfected with hARs or rA_{2A} ARs, membranes were prepared in a two-step procedure. A first low-
31
32 speed step (1000 g), where cell fragments and nuclei were removed, was followed by a high-speed
33
34 centrifugation (100 000g) to sediment the crude membrane fraction. The resulting membrane pellets
35
36 were resuspended in the buffer used for the respective binding experiments (hA₁ ARs: 50 mM
37
38 Tris/HCl buffer pH 7.4; hA_{2A}/rA_{2A} ARs: 50 mM Tris/HCl, 50 mM MgCl₂ pH 7.4; hA₃ ARs: 50 mM
39
40 Tris/HCl, 10 mM MgCl₂, 1 mM EDTA, pH 8.25), frozen in liquid nitrogen, and stored in aliquots at
41
42 -80 °C.
43
44
45

46
47 *Radioligand binding.* The affinity of compounds **1–21** for the human AR subtypes, hA₁, hA_{2A}, hA₃,
48
49 was determined with radioligand competition experiments in CHO cells that were stably transfected
50
51 with the individual receptor subtypes. The radioligands used were 1.0 nM [³H]CCPA) for hA₁, 10
52
53 nM [³H]NECA for hA_{2A}/rA_{2A} and 1.0 nM [³H]HEMADO for hA₃ receptors. Results were expressed
54
55 as K_i values (dissociation constants), which were calculated with the program GraphPad
56
57 (GraphPAD Software, San Diego, CA, USA). Each concentration was tested three-five times in
58
59 triplicate and the values are given as the mean ± standard error (S.E.).
60

1
2
3
4
5 The potency of antagonists at the hA_{2B} receptor (expressed on CHO cells) was determined by
6 inhibition of NECA- stimulated adenylyl cyclase activity.
7

8
9 *GloSensor cAMP Assay.* Functional A_{2A} and A_{2B} activity was determined as described earlier.^{66, 67}

10 Briefly, cells stably expressing the hA_{2A} or hA_{2B} AR and transiently the biosensor, were harvested
11 and incubated in equilibration medium containing a 3% v/v GloSensor cAMP reagent stock
12 solution, 10% FBS, and 87% CO₂ independent medium. After 2 h of incubation at rt, cells were
13 dispensed in the wells of a 384-well plate and NECA reference agonist or the understudy
14 compounds, at different concentrations, were added. When compounds were unable to stimulate the
15 cAMP production they were studied as antagonists. In particular, the antagonist profile was
16 evaluated by assessing the ability of these compounds to counteract NECA-induced increase of
17 cAMP accumulation.
18
19
20
21
22
23
24
25
26
27
28

29 Responses were expressed as percentage of the maximal relative luminescence units (RLU).

30 Concentration–response curves were fitted by a nonlinear regression with the Prism programme.

31 The antagonist profile of the compounds was expressed as IC₅₀, which is the concentration of
32 antagonists that produces 50% inhibition of the agonist effect. Each concentration was tested three-
33 five times in triplicate and the values are given as the mean ± S.E.⁶⁸
34
35
36
37
38
39

40
41 **Microglia Assays.** *Cell cultures.* Primary cultures of microglia were obtained according to the a
42 previously described method.⁶⁹ Briefly, the cerebral cortex of newborn (P1–P3) Sprague–Dawley
43 rats (Harlan, Italy) was dissociated in Hanks' balanced salt solution containing 0.5% trypsin/EDTA
44 and 1% DNase (Sigma) for 30 min at 37 °C. The suspension was mechanically homogenized and
45 filtered. Cells were plated in high-glucose DMEM with 20% FBS. Confluent primary microglia
46 cultures were used to isolate microglia by shaking. The purity of microglia cultures was determined
47 immunocytochemically by staining for Iba1 (Wako, Italy). Cells were fixed in 4%
48 paraformaldehyde, then incubated with the antibody (1:200), and visualized using Alexa Fluor-
49 conjugated secondary antibody. Nuclei were stained with 4,6-diamidino-2-phenylindole
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 dihydrochloride. Iba1-positive cells were 95–98% in microglia cultures. Experiments were
6
7 performed 10 days after cell isolation. Formal approval to conduct the experiments described was
8
9 obtained from the Animal Subjects Review Board of the University of Florence.

10
11 *Cell viability assay.* Cell viability was evaluated by the reduction of 3-(4,5-dimethylthiazol-2-yl)-
12
13 2,5-diphenyltetrazolium bromide (MTT) as an index of mitochondrial compartment functionality.
14
15 After treatments and an extensive washing, 1mg/ml MTT was added into each well and incubated
16
17 for 2 h at 37 °C. After washing, the formazan crystals were dissolved in 100 µl dimethyl sulfoxide.
18
19 The absorbance was measured at 580 nm. Experiments were performed in quadruplicate on at least
20
21 three different cell batches.
22
23

24
25 *Superoxide dismutase (SOD)-inhibitable superoxide anion ($O_2^{\bullet-}$) production evaluation by*
26
27 *cytochrome C assay.* Microglia was plated in six-well plates (5×10^5 /well) and grown until
28
29 confluent. Cells were then incubated with or without 100 µM oxaliplatin in serum-free DMEM
30
31 containing cytochrome C (1 mg/ml) for 4 h at 37 °C, in the absence or presence of 10 µM tested
32
33 compounds. Nonspecific cytochrome C reduction was evaluated by carrying out tests in the
34
35 presence of bovine SOD (300 mU/ml). The supernatants were collected, and the optical density was
36
37 spectrophotometrically measured at 550 nm. After the nonspecific absorbance was subtracted, the
38
39 SOD-inhibitable $O_2^{\bullet-}$ amount was calculated by using an extinction coefficient of $2.1 \times 10^4 \text{ M}^{-1}$
40
41 cm^{-1} and expressed as µM/mg protein/4 h. The 4 h incubation interval was chosen on the basis of
42
43 preliminary experiments, which showed poor reliability for longer cytochrome c exposure to the
44
45 cellular environment.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 *Catalase activity.* Enzymatic activity was measured in microglia culture. After incubation and
6
7 treatments, cells were washed once with PBS and scraped with PBS on ice. Cells were then
8
9 collected, subjected to a freeze–thaw cycle and centrifuged (13,000×g for 10 min at 4 °C). Catalase
10
11 activity was measured in the supernatant by Amplex Red Catalase Assay Kit (Invitrogen, Monza,
12
13 Italy) following the manufacturer’s instructions. Protein concentration was quantified by
14
15 bicinchoninic acid assay (Sigma–Aldrich, Milan, Italy). Catalase activity for each sample was
16
17 normalized to protein concentration. Control conditions in the absence of treatment were set as
18
19 100%.
20
21

22
23 **In vivo tests.** *Animals.* Male CD-1 albino mice (Envigo, Varese, Italy) weighing approximately 22–
24
25 25 g at the beginning of the experimental procedure, were used. Animals were housed in Ce.S.A.L
26
27 (Centro Stabulazione Animali da Laboratorio, University of Florence) and used at least 1 week after
28
29 their arrival. Ten mice were housed per cage (size 26 × 41 cm). Animals were fed a standard
30
31 laboratory diet and tap water *ad libitum*, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7
32
33 a.m. All animal manipulations were carried out according to the Directive 2010/63/EU of the
34
35 European parliament and of the European Union council (22 September 2010) on the protection of
36
37 animals used for scientific purposes. The ethical policy of the University of Florence complies with
38
39 the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH
40
41 Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal
42
43 approval to conduct the experiments described was obtained from the Animal Subjects Review
44
45 Board of the University of Florence. Experiments involving animals have been reported according
46
47 to ARRIVE guideline. All efforts were made to minimize animal suffering and to reduce the
48
49 number of animals used.
50
51
52
53
54

55
56 *Oxaliplatin-induced neuropathic pain model and pharmacological treatments.* Mice treated with
57
58 oxaliplatin (2.4 mg kg⁻¹) were administered intraperitoneally (i.p.) on days 1-2, 5-9, 12-14 (10 i.p.
59
60

1
2
3
4
5 injections).⁷⁰ Oxaliplatin was dissolved in 5% glucose solution. Control animals received an
6
7 equivalent volume of vehicle. Behavioural tests were performed on day 14. Tested compounds were
8
9 suspended in 1% carboxymethylcellulose sodium salt (CMC, Sigma-Aldrich, Milan, Italy) and *per*
10
11 *os* (p.o.) acutely administered.

12
13
14 *Cold plate test.* The animals were placed in a stainless steel box (12 cm × 20 cm × 10 cm) with a
15
16 cold plate as floor. The temperature of the cold plate was kept constant at 4 °C ± 1 °C. Pain-related
17
18 behaviour (licking of the hind paw) was observed and the time (seconds) of the first sign was
19
20 recorded. The cut-off time of the latency of paw lifting or licking was set at 60s.^{71,72}

21
22
23 *Statistical analysis.* Behavioural measurements were performed on 12 mice for each treatment
24
25 carried out in 2 different experimental sets. Results were expressed as mean ± S.E.M. The analysis
26
27 of variance of behavioural data was performed by one way ANOVA, a Bonferroni's significant
28
29 difference procedure was used as post-hoc comparison. *P* values of less than 0.05 or 0.01 were
30
31 considered significant. Investigators were blind to all experimental procedures. Data were analysed
32
33 using the “Origin 9” software (OriginLab, Northampton, USA).
34
35
36
37
38
39

40 **SUPPORTING INFORMATION**

41
42
43 -Stability Studies.

44
45
46 -Molecular formula strings (CSV).

47
48
49 -PDB coordinates of the 3D structure of the hA_{2A} adenosine receptor (PDB code 5NM4) and hA₁
50
51 adenosine receptor (PDB code 5N2S). The two structures were added to hydrogen atoms and
52
53 missing loop segments and energetically minimized.
54
55

56
57 Authors will release the atomic coordinates upon article publication.
58
59
60

1
2
3
4
5 **ACKNOWLEDGMENTS.** The work was financially supported by the Italian Ministry for
6
7 University and Research (MIUR, PRIN 2010-2011, 20103W4779_004 project), the University of
8
9 Florence (Fondi Ateneo Ricerca) and Fondazione Cassa di Risparmio di Firenze (2018).
10
11
12
13
14

15 **ABBREVIATIONS USED**

16
17 AR, adenosine receptor; BHT, 3,5-ditert-butyl-4-hydroxytoluene; CHO, chinese hamster ovary;
18
19 CCPA, 2-chloro-N⁶-cyclopentyladenosine; CMC, carboxymethylcellulose; DMME, Dulbecco's
20
21 modified Eagle's medium; EL, extracellular loop; FBS, fetal bovine serum; HEMADO, (2-(1-
22
23 hexynyl)-N-methyladenosine; KEE, ketoprofene ethylester; MOE, molecular operating
24
25 environment; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; mw,
26
27 microwave; NECA, 5'-(N-ethyl-carboxamido)adenosine; RMS, root mean square; SOD, superoxide
28
29 dismutase; TM, transmembrane
30
31
32
33
34
35
36

37 **REFERENCES**

- 38
39
40
41 1. Borea, P.A.; Gessi S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine
42
43 Receptors: the State of Art. *Physiol. Rev.* **2018**, *98*, 1591-1625.
44
45
46 2. van Waarde, A.; Dierckx, R. A.J.O.; Zhou, X.; Khanapur, S.; Tsukada, H.; Ishiwata, K.;
47
48 Luurtsema, G.; de Vries, E.F.J.; Elsinga, P.H. Potential Therapeutic Applications of
49
50 Adenosine A_{2A} Receptor Ligands and Opportunities for A_{2A} Receptor Imaging. *Med. Res.*
51
52 *Rev.* **2018**, *38*, 5-56.
53
54
55 3. Borea, P.A.; Gessi S.; Merighi S.; Varani, K. Adenosine as Multi-Signalling Guardian
56
57 Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?.
58
59 *Trends Pharmacol. Sci.* **2016**, *37*, 419-434.
60

- 1
2
3
4
5 4. Stockwell, J.; Jakova E.; Cayabyab, F.S. Adenosine A₁ and A_{2A} Receptors in the Brain:
6
7 Current Research and their Role in Neurodegeneration. *Molecules*, **2017**, *22*, 676.
8
- 9
10 5. Borea P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pathological Overproduction:
11
12 the Bad Side of Adenosine. *Br. J. Pharmacol.* **2017** *174*, 1945-1960.
13
- 14 6. Hasko, G.; Pacher, P.; Vizi, E.S.; Illes, P. Adenosine Receptor Signaling in the Brain
15
16 Immune System. *Trends Pharmacol. Sci.* **2005**, *26*, 511–516.
17
- 18 7. Martín, E.D.; Fernández, M.; Perea, G.; Pascual, O.; Haydon, P.G.; Araque, A.; Ceña, V.
19
20 Adenosine Released by Astrocytes Contributes to Hypoxia-Induced Modulation of Synaptic
21
22 Transmission. *Glia* **2007**, *55*, 36–45.
23
- 24 8. Gomes, C.; Ferreira, R.; George, J.; Sanches, R.; Rodrigues, D.I.; Gonçalves, N.; Cunha,
25
26 R.A. Activation of Microglial Cells Triggers a Release of Brain-Derived Neurotrophic
27
28 Factor (BDNF) Inducing their Proliferation in an Adenosine A_{2A} Receptor-Dependent
29
30 Manner: A_{2A} Receptor Blockade Prevents BDNF Release and Proliferation of Microglia. *J.*
31
32 *Neuroinflammation* **2013**, *10*, 16.
33
- 34 9. Santiago, A.R.; Baptista, F.I.; Santos, P.F.; Cristovao, G.; Ambrosio, A.F.; Cunha, R.A.;
35
36 Gomes, C.A. Role of Microglia Adenosine A_{2A} Receptors in Retinal and Brain
37
38 Neurodegenerative Diseases. *Mediators of Inflammation* **2014**, ID 465694, 13 page.
39
- 40 10. Pintor, A.; Quarta, D.; Pèzzola, A.; Reggio, R.; Popoli, P. SCH 58261 an Adenosine A_{2A}
41
42 Receptor Antagonist Reduces, only at Low Doses, K(+)-Evoked Glutamate Release in the
43
44 Striatum. *Eur. J. Pharmacol.* **2001**, *421*, 177–180.
45
- 46 11. Popoli, P.; Pintor, A.; Domenici, M.R.; Frank, C.; Tebano, M.T.; Pèzzola, A.; Scarchilli, L.;
47
48 Quarta, D.; Reggio, R.; Malchiodi-Albedi, F.; Falchi, M.; Massotti, M. Blockade of Striatal
49
50 Adenosine A_{2A} Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-
51
52 Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in
53
54 Neurodegenerative Diseases of the Striatum. *J. Neurosci.* **2002**, *22*, 1967–1975.
55
56
57
58
59
60

- 1
2
3
4
5 12. Pedata, F.; Dettori, I.; Coppi, E.; Melani, A.; Fusco, I.; Corradetti, R.; Pugliese, A.M.
6
7 Purinergic Signalling in Brain Ischemia. *Neuropharmacology* **2016**, *104*, 105-130.
8
9
10 13. Nishizaki, T.; Nagai, K.; Nomura, T.; Tada, H.; Kanno, T.; Tozaki, H.; Li, X.X.; Kondoh,
11
12 T.; Kodama, N.; Takahashi, E.; Sakai, N.; Tanaka, K.; Saito, N. A New Neuromodulatory
13
14 Pathway with a Glial Contribution Mediated via A(2A) Adenosine Receptors. *Glia* **2002**,
15
16 *39*, 133–147.
17
18
19 14. Nishizaki, T. ATP- and Adenosine-mediated Signaling in the Central Nervous System:
20
21 Adenosine Stimulates Glutamate Release from Astrocytes via A_{2A} Adenosine Receptors. *J.*
22
23 *Pharmacol. Sci.* **2004**, *94*, 100–102.
24
25
26 15. Bura, S. A.; Nadal, X.; Ledent, C.; Maldonado, R.; Valverde, O. A_{2A} Adenosine Receptor
27
28 Regulates Glia Proliferation and Pain after Peripheral Nerve Injury. *Pain* **2008**, *140*, 95-103.
29
30
31 16. Zhuo, M. Neuronal Mechanism for Neuropathic Pain. *Mol. Pain* **2007**, *3*, 14.
32
33
34 17. Kim, H.K.; Park, S.K.; Zhou, J.L.; Tagliatela, G.; Chung, K.; Coggeshall, R.E.; Chung
35
36 J.M. Reactive Oxygen Species (ROS) Play an Important Role in Rat Model of Neuropathic
37
38 Pain. *Pain* **2004**, *111*, 116-124.
39
40
41 18. Naik, A.K.; Tandan, S.K.; Dudhgaonkar, S.P.; Jadhav, S.H.; Kataria, M.; Prakash, V.R.
42
43 Kumar, D. Role of Oxidative Stress in Pathophysiology of Peripheral Neuropathy and
44
45 Modulation by N-acetyl-L-cysteine in Rats. *Eur. J. Pain* **2006**, *10*, 573–579.
46
47
48 19. Areti, A.; Ganesh, Y.V.; Naidu, V.G.M.; Kumar, A. Oxidative Stress and Nerve Damage:
49
50 Role in Chemotherapy Induced Peripheral Neuropathy. *Redox Biology* **2014**, *2*, 289-295.
51
52
53 20. Carrasco, C.; Naziroğlu, M.; Rodríguez, A.B.; Pariente, J.A. Neuropathic Pain: Delving into
54
55 the Oxidative Origin and the Possible Implication of Transient Receptor Potential Channels.
56
57 *Front. Physiol.* **2018**, *9*, 95.
58
59
60 21. Sawynok, J. Adenosine Receptor Targets for Pain. *Neuroscience* **2016**, *338*, 1–18.

- 1
2
3
4
5 22. Godfrey, L.; Yan, L.; Clarke, G.D.; Ledent, C.; Kitchen, I.; Hourani, S.M.O. Modulation of
6
7 Paracetamol Antinociception by Caffeine and Selective Adenosine A₂ Receptor Antagonists
8
9 in Mice. *Eur. J. Pharmacol.* **2006**, *531*, 80–86.
10
11
12 23. Hussey, M.J.; Clarke, G.D.; Ledent, C.; Hourani, S.M.O.; Kitchen, I. Reduced Response to
13
14 the Formalin Test and Lowered Spinal NMDA Glutamate Receptor Binding in Adenosine
15
16 A_{2A} Receptor Knockout Mice. *Pain* **2007**, *129*, 287–294.
17
18
19 24. Sawynok, J.; Reid, A.R. Caffeine Inhibits Antinociception by Acetaminophen in the
20
21 Formalin Test by Inhibiting Spinal Adenosine A₁ Receptors. *Eur. J. Pharmacol.* **2012**, *674*,
22
23 248–254.
24
25
26 25. Varano, F.; Catarzi, D.; Vincenzi, F.; Betti, M.; Falsini, M.; Ravani, A.; Borea, P.A.; Colotta,
27
28 V.; Varani, K. Design, Synthesis, and Pharmacological Characterization of 2 - (2-
29
30 Furanyl)thiazolo[5,4-*d*]pyrimidine-5,7-diamine Derivatives: New Highly Potent A_{2A}
31
32 Adenosine Receptor Inverse Agonists with Antinociceptive Activity. *J. Med. Chem.* **2016**,
33
34 *59*, 10564-10576.
35
36
37 26. Squarcialupi, L.; Betti, M.; Catarzi, D.; Varano, F.; Falsini, M.; Ravani, A.; Pasquini, S.;
38
39 Vincenzi, F.; Salmaso, V.; Sturlese, M.; Varani, K.; Moro, S.; Colotta V. The Role of 5-
40
41 Arylalkylamino- and 5-Piperazino- Moieties on the 7-Aminopyrazolo[4,3-*d*]pyrimidine
42
43 Core in Affecting Adenosine A₁ and A_{2A} Receptor Affinity and Selectivity Profiles. *J. Enz.*
44
45 *Inhib. Med. Chem.* **2017**, *32*, 248-263.
46
47
48 27. Falsini, M.; Squarcialupi, L.; Catarzi, D.; Varano, F.; Betti, M.; Dal Ben, D.; Marucci, G.;
49
50 Buccioni, M.; Volpini, R.; De Vita, T.; Cavalli, A.; Colotta, V. The 1,2,4-Triazolo[4,3-
51
52 a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor
53
54 Antagonists. Structural Investigations to Target the A_{2A} Receptor. *J. Med. Chem.* **2017**, *60*,
55
56 5772-5790.
57
58
59
60

- 1
2
3
4
5 28. Gessi, S.; Bencivenni, S.; Battistello, E.; Vincenzi, F.; Colotta, V.; Catarzi, D.; Varano, F.;
6
7 Merighi, S.; Borea, P.A.; Varani, V. Inhibition of A_{2A} Adenosine Receptor Signaling in
8
9 Cancer Cells Proliferation by the Novel Antagonist TP455. *Front. Pharmacol.* **2017**, *8*, 888.
10
11
12 29. Catarzi, D.; Varano, F.; Falsini, M.; Varani, K.; Vincenzi, F.; Colotta, V. Development of
13
14 Novel Pyridazinone-based Adenosine Receptor Ligands. *Bioorg. Med. Chem. Lett.* **2018**, *28*,
15
16 1484-1489.
17
18
19 30. Varano, F.; Catarzi, D.; Falsini, M.; Vincenzi, F.; Pasquini, S.; Varani, K.; Colotta, V.
20
21 Identification of Novel Thiazolo[5,4-d]pyrimidine Derivatives as Human A₁ and A_{2A}
22
23 Adenosine Receptor Antagonists/Inverse Agonists. *Bioorg. Med. Chem.* **2018**, *26*, 3688-
24
25 3695.
26
27
28 31. Varano, F.; Catarzi, D.; Vincenzi, F.; Falsini, M.; Pasquini, S.; Borea, P.A.; Colotta, V.;
29
30 Varani, K. Structure-Activity Relationship Studies and Pharmacological Characterization of
31
32 N5-Heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based
33
34 Derivatives as Inverse Agonists at Human A_{2A} Adenosine Receptor. *Eur. J. Med. Chem.*
35
36 **2018**, *155*, 552-561.
37
38
39 32. Varano, F.; Catarzi, D.; Falsini, M.; Dal Ben, D.; Buccioni, M.; Marucci, G.; Volpini, R.;
40
41 Colotta, V. Novel Human Adenosine Receptor Antagonists Based on the 7-Amino-
42
43 thiazolo[5,4-d]pyrimidine Scaffold. Structural Investigations at the 2-, 5- and 7-Positions to
44
45 Enhance Affinity and Tune Selectivity. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 563-569.
46
47
48 33. Falsini, M.; Catarzi, D.; Varano, F.; Dal Ben, D.; Marucci, G.; Buccioni, M.; Volpini, R.; Di
49
50 Cesare Mannelli, L. Ghelardini, C.; Colotta, V. Novel 8-Amino-1,2,4-triazolo[4,3-a]pyrazin-
51
52 3-one Derivatives as Potent Human Adenosine A₁ and A_{2A} Receptor Antagonists.
53
54 Evaluation of Their Protective Effect against β -Amyloid-induced Neurotoxicity in SH-
55
56 SY5Y Cells. *Bioorg. Chem.* **2019**, *87*, 380-394.
57
58
59
60

- 1
2
3
4
5 34. Betti, M.; Catarzi, D.; Varano, F.; Falsini, M.; Varani, K.; Vincenzi, F.; Dal Ben, D.;
6
7 Lambertucci, C.; Colotta, V. The Aminopyridine-3,5-Dicarbonitrile Core for the Design of
8
9 New non-Nucleoside-like Agonists of the Human Adenosine A_{2B} Receptor. *Eur. J. Med.*
10
11 *Chem.* **2018**, *150*, 127-139.
12
13
14 35. Bonsack, F.; Cargill, H.; Alleyne J.R.; Sukumari-Ramesh, S. Resveratrol Attenuates
15
16 Neurodegeneration and Improves Neurological Outcomes after Intracerebral Hemorrhage in
17
18 Mice. *Front. Cell. Neurosci.* **2017**, *11*, 228.
19
20
21 36. Gay, N.H.; Phopin, K.; Suwanjang, W.; Songtawee, N, Ruankham, W.; Wongchitrat, P.;
22
23 Prachayasittikul, S.; Prachayasittikul, V. Neuroprotective Effects of Phenolic and
24
25 Carboxylic Acids on Oxidative Stress-Induced Toxicity in Human Neuroblastoma SH-
26
27 SY5Y. *Cells Neurochem. Res.* **2018**, *43*, 619-636.
28
29
30 37. Benfeito, S.; Oliveira, C.; Soares, P.; Fernandes, C.; Silva, T.; Teixeira, J.; Borges, F.
31
32 Antioxidant Therapy: Still in Search of the “Magic Bullet”. *Mitochondrion* **2013**, *13*,
33
34 427–435.
35
36
37 38. Yehye, W.A.; Rahman, N.A.; Ariffin, A.; Abd Hamid, S.B.; Alhadi, A.A.; Kadir, F.A.;
38
39 Yaeghoobi, M. Understanding the Chemistry behind the Antioxidant Activities of Butylated
40
41 Hydroxytoluene (BHT): a Review. *Eur. J. Med. Chem.* **2015**, *101*, 295-312.
42
43
44 39. Seifar, F.; Khalili, M.; Khaledyan, H.; Amiri Moghadam, S.; Izadi, A.; Azimi, A.; Shakouri
45
46 S.K. α -Lipoic Acid, Functional Fatty Acid, as a Novel Therapeutic Alternative for Central
47
48 Nervous System Diseases: A Review. *Nutr. Neurosci.* **2019**, *22*, 306-312.
49
50
51 40. Molz, P.; Schröder, N. Potential Therapeutic Effects of Lipoic Acid on Memory Deficits
52
53 Related to Aging and Neurodegeneration. *Front. Pharmacol.* **2017**, *8*, 849.
54
55
56 41. Mostacci, B.; Liguori, R.; Cicero, A.F.G. Nutraceutical Approach to Peripheral
57
58 Neuropathies: Evidence from Clinical Trials. *Curr. Drug Metab.* **2018**, *19*, 460-468.
59
60

- 1
2
3
4
5 42. Papanas, N.; Ziegler, D. Efficacy of α -Lipoic Acid in Diabetic Neuropathy. *Expert Opin.*
6
7 *Pharmacother.* **2014**, *15*, 2721-2731.
8
9
10 43. Agathos, E.; Tentolouris, A.; Eleftheriadou, I.; Katsaouni, P.; Nemtzas, I.; Petrou, A.;
11 Papanikolaou, C.; Tentolouris, N. Effect of α -Lipoic Acid on Symptoms and Quality of Life
12 in Patients with Painful Diabetic Neuropathy. *J. Int. Med. Res.* **2018**, *46*, 1779–1790.
13
14
15 44. Matychuk, V.S.; Potopnyk, M.A.; Luboradzki, R.; Obushak, M.D. A New Method for the
16 Synthesis of 1-Aryl-1,2,4-triazole Derivatives. *Synthesis*, **2011**, *11*, 1799–1803.
17
18
19 45. Al-Rifai, N.; Rucker, H.; Amslinger, S. Opening or Closing the Lock? When Reactivity is
20 the Key to Biological Activity. *Chem. Eur. J.* **2013**, *19*, 15384–15395.
21
22
23 46. Boulahjar, R.; Rincon Arias, A.; Bolteau, R.; Renault, N.; Coevoet, M.; Barczyk, A.;
24 Duroux, R.; Yous, S.; Melnyk, P.; Agouridas, L. Design and Synthesis of 2,6-Disubstituted-
25 8-Amino-Imidazo[1,2-a]Pyridines, a Promising Privileged Structure. *Bioorg. Med. Chem.*
26 **2018**, *26*, 3296–3307.
27
28
29 47. Moine, E.; Dimier-Poisson I.; Enguehard-Gueiffier, C.; Logè, C.; Penichon, M.; Moirè, N.;
30 Delehouzè, C.; Foll-Josselin, B.; Ruchaud, S.; Bach, S.; Gueiffier, A.; Debierre-Grockiego,
31 F.; Denevault-Sabourin, C. Development of New Highly Potent Imidazo[1,2-b]pyridazines
32 Targeting Toxoplasma Gondii Calcium-Dependent Protein Kinase 1. *Eur. J. Med. Chem.*
33 **2015**, *105*, 80-105.
34
35
36 48. Fan, Y.; Luo, Y.; Ma, C. Synthesis and Cytotoxic Evaluation of Combretastatin A-4
37 Analogues of Benzo[b]Furans. *Monatsh. Chem.* **2017**, *148*, 1823–1832.
38
39
40 49. Nishinaga, A.; Shimizu, T.; Toyoda, Y.; Matsuura, T. Oxygenation of 2,6-di-Tert-
41 Butylphenols Bearing an Electron-Withdrawing Group in the 4-Position, *J. Org. Chem.*
42 **1982**, *47*, 2278-2285.
43
44
45 50. Molecular Operating Environment; C.C.G., I., 1255 University St., Suite 1600, Montreal,
46 Quebec, Canada, H3B 3X3.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5 51. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and Validation of a
6
7 Genetic Algorithm for Flexible Docking. *J. Mol. Biol.* **1997**, *267*, 727-748.
8
9
10 52. Weinert, T.; Olieric, N.; Cheng, R.; Brunle, S.; James, D.; Ozerov, D.; Gashi, D.; Vera, L.;
11
12 Marsh, M.; Jaeger, K.; Dworkowski, F.; Panepucci, E.; Basu, S.; Skopintsev, P.; Dore, A.
13
14 S.; Geng, T.; Cooke, R.M.; Liang, M.; Prota, A.E.; Panneels, V.; Nogly, P.; Ermler, U.;
15
16 Schertler, G.; Hennig, M.; Steinmetz, M.O.; Wang, M.; Standfuss, J. Serial Millisecond
17
18 Crystallography for Routine Room-Temperature Structure Determination at Synchrotrons.
19
20 *Nat. Commun* **2017**, *8*, 542.
21
22
23 53. Cheng, R.K.Y.; Segala, E.; Robertson, N.; Deflorian, F.; Dore, A.S.; Errey, J.C.; Fiez-
24
25 Vandal, C.; Marshall, F.H.; Cooke, R.M. Structures of Human A₁ and A_{2A} Adenosine
26
27 Receptors with Xanthines Reveal Determinants of Selectivity. *Structure* **2017**, *25*, 1275-
28
29 1285 e4.
30
31
32 54. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.;
33
34 IJzerman, A.P.; Stevens, R. C. The 2.6 Angstrom Crystal Structure of a Human A_{2A}
35
36 Adenosine Receptor Bound to an Antagonist. *Science* **2008**, *322*, 1211-1217.
37
38
39 55. Dal Ben, D.; Lambertucci, C.; Marucci, G.; Volpini, R.; Cristalli, G. Adenosine Receptor
40
41 Modeling: What does the A_{2A} Crystal Structure Tell Us? *Curr. Top. Med. Chem.* **2010**, *10*,
42
43 993-1018.
44
45
46 56. Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S. Clinical Aspects and Molecular Basis of
47
48 Oxaliplatin Neurotoxicity: Current Management and Development of Preventive Measures.
49
50 *Semin. Oncol.* **2002**, *29*, Suppl 5, 21-33.
51
52
53 57. Di Cesare Mannelli, L.; Pacini, A.; Bonaccini, L.; Zanardelli, M.; Mello, T.; Ghelardini, C.
54
55 Morphologic Features and Glial Activation in Rat Oxaliplatin-Dependent Neuropathic Pain.
56
57 *J. Pain* **2013**, *14*, 1585–1600.
58
59
60

- 1
2
3
4
5 58. Di Cesare Mannelli, L.; Pacini, A.; Micheli, L.; Tani, A.; Zanardelli, M.; Ghelardini, C.
6
7 Glial Role in Oxaliplatin-Induced Neuropathic Pain. *Exp. Neurol.* **2014**, *261*, 22–33.
8
9
10 59. Di Cesare Mannelli, L., Zanardelli, M.; Failli, P.; Ghelardini, C. Oxaliplatin-Induced
11
12 Neuropathy: Oxidative Stress as Pathological Mechanism. Protective Effect of Silibinin. *J.*
13
14 *Pain* **2012**, *13*, 276-284.
15
16
17 60. Di Cesare Mannelli, L.; Zanardelli, M.; Failli, P.; Ghelardini, C. Oxaliplatin-Induced
18
19 Oxidative Stress in Nervous System-Derived Cellular Models: Could It Correlate with in
20
21 vivo Neuropathy? *Free Radic. Biol. Med.* **2013**, *6*, 143-150.
22
23
24 61. Zanardelli, M.; Micheli, L.; Cinci, L.; Failli, P.; Ghelardini, C.; Di Cesare Mannelli, L.
25
26 Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPAR γ Agonism as Preventive
27
28 Pharmacological Approach. *PLoS One* **2014**, *9*, e102758.
29
30
31 62. Connell, B.J.; Saleh, M.C.; Khan, B.V.; Rajagopal, D.; Saleh, T.M., UPEI-100, a Conjugate
32
33 of Lipoic Acid and Apocynin Mediates Neuroprotection in a Rat Model of
34
35 Ischemia/Reperfusion. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2012**, *302*, R886-R895.
36
37
38 63. Saleh, M.C.; Connell, B.J.; Rajagopal, D.; Khan, B.V.; Abd-El-Aziz, A.S.; Kucukkaya, I.,
39
40 Saleh, T. M., Co-administration of Resveratrol and Lipoic Acid or Their Synthetic
41
42 Combination, Enhances Neuroprotection in a Rat Model of Ischemia/Reperfusion. *PLoS*
43
44 *One* **2014**, *9*, 1-9.
45
46
47 64. Teodori, E., Dei, S., Bartolucci, G., Perrone, M.G., Manetti, D., Romanelli, M.N., Contino,
48
49 M., Colabufo, N.A. Structure–Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-
50
51 1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. *Chem. Med.*
52
53 *Chem.* **2017**, *12*, 1369-1379.
54
55
56 65. Marshall, A.G.; Hendrickson, C.L. High-resolution Mass Spectrometers. *Annu. Rev. Anal.*
57
58 *Chem.* **2008**, *1*, 579-599.
59
60

- 1
2
3
4
5 66. Thomas, A.; Buccioni, M.; Dal Ben, D.; Lambertucci, C.; Marucci, G.; Santinelli, C.;
6
7 Spinaci, A.; Kachler, S.; Klotz, K.- N.; Volpini, R. The Length and Flexibility of the 2-
8
9 Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human
10
11 A_{2A} Adenosine Receptor. *Chem. Med. Chem.* **2016**, *11*, 1829-1839.
12
13
14 67. Buccioni, M.; Santinelli, C.; Angeli, P.; Dal Ben, D.; Lambertucci, C.; Thomas, A.; Volpini,
15
16 R.; Marucci, G. Overview on Radiolabel-Free in vitro Assays for GPCRs. *Mini Rev. Med.*
17
18 *Chem.* **2017**, *17*, 3-14.
19
20
21 68. Buccioni, M.; Marucci, G.; Dal Ben, D.; Giacobbe, D.; Lambertucci, C.; Soverchia, L.;
22
23 Thomas, A.; Volpini, R.; Cristalli, G. Innovative Functional cAMP Assay for Studying G
24
25 Protein-Coupled Receptors: Application to the Pharmacological Characterization of GPR17.
26
27 *Purinerg. Signal.* **2011**, *7*, 463-468.
28
29
30 69. McCarty, K.D.; de Vellis, J. Preparation of Separate Astroglial and Oligodendroglial Cell
31
32 Cultures from Rat Cerebral Tissue. *J. Cell. Biol.* **1980**, *85*, 890-902.
33
34
35 70. Di Cesare Mannelli, L.; Lucarini, E.; Micheli, L.; Mosca, I.; Ambrosino, P.; Soldovieri,
36
37 M.V.; Martelli, A.; Testai, L.; Taglialatela, M.; Calderone, V.; Ghelardini, C. Effects of
38
39 Natural and Synthetic Isothiocyanate-based H_2S -Releasers Against Chemotherapy-Induced
40
41 Neuropathic Pain: Role of Kv7 Potassium Channels. *Neuropharmacology* **2017**, *121*, 49-59.
42
43
44 71. Di Cesare Mannelli, L.; Bani, D.; Bencini, A.; Brandi, M.L.; Calosi, L.; Cantore, M.;
45
46 Carossino, A.M.; Ghelardini, C.; Valtancoli, B.; Failli, P. Therapeutic Effects of the
47
48 Superoxide Dismutase Mimetic Compound MnIIME2DO2A on Experimental Articular Pain
49
50 in Rats. *Mediators Inflamm.* **2013**, ID 905360.
51
52
53 72. Failli, P.; Bani, D.; Bencini, A.; Cantore, M.; Di Cesare Mannelli, L.; Ghelardini, C.; Giorgi,
54
55 C.; Innocenti, M.; Rugi, F.; Spepi, A.; Udisti, R.; Valtancoli, B. A Novel Manganese
56
57 Complex Effective as Superoxide Anion Scavenger and Therapeutic Agent Against Cell and
58
59 Tissue Oxidative Injury. *J. Med. Chem.* **2009**, *52*, 7273-7283.
60

Table of Contents Graphic

